| 3 |
Reduction, 17beta-estradiol synthesis by ovarian granulosa cells |
Reduction, 17beta-estradiol synthesis by ovarian granulosa cells |
Cellular |
| 8 |
Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity |
Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity |
Cellular |
| 9 |
Activation, 5HT2c |
Activation, 5HT2c |
Molecular |
| 10 |
Acetylcholine accumulation in synapses |
ACh Synaptic Accumulation |
Cellular |
| 12 |
Acetylcholinesterase (AchE) Inhibition |
AchE Inhibition |
Cellular |
| 17 |
Altered gene expression, AHR nuclear translocator (ARNT)-dependent pathway |
Altered expression of AHR/ARNT pathway-dependent genes |
Molecular |
| 18 |
Activation, AhR |
Activation, AhR |
Molecular |
| 21 |
Altered regulation, Alpha hemoglobin |
Altered regulation, Alpha hemoglobin |
Cellular |
| 25 |
Agonism, Androgen receptor |
Agonism, Androgen receptor |
Molecular |
| 26 |
Antagonism, Androgen receptor |
Antagonism, Androgen receptor |
Molecular |
| 27 |
N/A, Androgen receptor, Antagonism |
N/A, Androgen receptor, Antagonism |
Molecular |
| 28 |
Reduction, Angiogenesis |
Reduction, Angiogenesis |
Molecular |
| 29 |
Reduction in, Angiogenic sprouts |
Reduction in, Angiogenic sprouts |
|
| 35 |
Decrease, Aromatase (Cyp19a1) |
Decrease, Aromatase (Cyp19a1) |
Cellular |
| 36 |
Inhibition, Aromatase |
Inhibition, Aromatase |
Molecular |
| 39 |
Increased Cholinergic Signaling |
Increased Cholinergic Signaling |
Organ |
| 40 |
Decrease, Mitochondrial ATP production |
Decrease, Mitochondrial ATP production |
Cellular |
| 41 |
Inhibition, Bile Salt Export Pump (ABCB11) |
Inhibition, Bile Salt Export Pump (ABCB11) |
Molecular |
| 46 |
Accumulation, Biological membranes |
Accumulation, Biological membranes |
Cellular |
| 49 |
Reduction, Ca and HCO3 transport to shell gland |
Reduction, Ca and HCO3 transport to shell gland |
Tissue |
| 50 |
Increase, Ca++ (intracellular) |
Increase, Ca++ (intracellular) |
Cellular |
| 51 |
Inhibition, Ca++ ATPase |
Inhibition, Ca++ ATPase |
Molecular |
| 52 |
Decreased, Calcium influx |
Decreased, Calcium influx |
Cellular |
| 54 |
Up Regulation, CD36 |
Up Regulation, CD36 |
Molecular |
| 55 |
Cell injury/death |
Cell injury/death |
Cellular |
| 57 |
Proliferation, Cell proliferation in the absence of cytotoxicity |
Proliferation, Cell proliferation in the absence of cytotoxicity |
Cellular |
| 59 |
Inhibition of Apoptosis in Altered Hepatic Foci, Changes in Cellular Growth Homeostasis |
Inhibition of Apoptosis in Altered Hepatic Foci, Changes in Cellular Growth Homeostasis |
|
| 60 |
Induction, Chitin degradation and resorption |
Induction, Chitin degradation and resorption |
|
| 64 |
Reduction, Ionotropic GABA receptor chloride channel conductance |
Reduction, Ionotropic GABA receptor chloride channel conductance |
Cellular |
| 66 |
Activation, ChREBP |
Activation, ChREBP |
Molecular |
| 68 |
Accumulation, Collagen |
Accumulation, Collagen |
Tissue |
| 75 |
N/A, Covalent binding to protein, possibly lysine residue |
N/A, Covalent binding to protein, possibly lysine residue |
Molecular |
| 77 |
Production, Critical Metabolites (CGA 330050 and CGA 265307) |
Production, Critical Metabolites (CGA 330050 and CGA 265307) |
Cellular |
| 78 |
Reduction, Cumulative fecundity and spawning |
Reduction, Cumulative fecundity and spawning |
Individual |
| 79 |
Inhibition, Cyclooxygenase activity |
Inhibition, Cyclooxygenase activity |
Molecular |
| 80 |
Up Regulation, CYP1A1 |
Up Regulation, CYP1A1 |
Molecular |
| 84 |
Up Regulation, CYP1B1 |
Up Regulation, CYP1B1 |
Molecular |
| 87 |
Release, Cytokine |
Release, Cytokine |
Cellular |
| 89 |
Synthesis, De Novo FA |
Synthesis, De Novo FA |
Cellular |
| 97 |
Alkylation, DNA |
Alkylation, DNA |
Molecular |
| 103 |
Increase, Ecdysone receptor agonism |
Increase, EcR agonism |
Molecular |
| 105 |
Inhibition, Mitochondrial Electron Transport Chain Complexes |
Inhibition, ETC complexes of the respiratory chain |
Molecular |
| 106 |
Reduction, Eggshell thickness |
Reduction, Eggshell thickness |
Tissue |
| 110 |
Impairment, Endothelial network |
Impairment, Endothelial network |
Cellular |
| 111 |
Agonism, Estrogen receptor |
Agonism, Estrogen receptor |
Molecular |
| 112 |
Antagonism, Estrogen receptor |
Antagonism, Estrogen receptor |
Molecular |
| 115 |
Increase, FA Influx |
Increase, FA Influx |
Cellular |
| 116 |
Activation, FAS |
Activation, FAS |
Molecular |
| 118 |
Formation, Formation of hemoglobin adducts |
Formation, Formation of hemoglobin adducts |
Cellular |
| 119 |
N/A, Gap |
N/A, Gap |
Tissue |
| 122 |
Activation, Glucocorticoid Receptor |
Activation, Glucocorticoid Receptor |
Molecular |
| 129 |
Reduction, Gonadotropins, circulating concentrations |
Reduction, Gonadotropins, circulating concentrations |
Organ |
| 130 |
Depletion, GSH |
Depletion, GSH |
Cellular |
| 131 |
Down Regulation, Gulcose-6-phosphate dehydrogenase |
Down Regulation, Gulcose-6-phosphate dehydrogenase |
Cellular |
| 134 |
Increased, Activation and Recruitment of Hepatic macrophages (Kupffer Cells) |
Increased, Activation and Recruitment of Hepatic macrophages (Kupffer Cells) |
Cellular |
| 139 |
N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects |
N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects |
Tissue |
| 140 |
Decreased, HSD17B10 expression |
Decreased, HSD17B10 expression |
Cellular |
| 142 |
Hyperplasia, Hyperplasia |
Hyperplasia, Hyperplasia |
Tissue |
| 145 |
Induction, IKB inhibitory protein |
Induction, IKB inhibitory protein |
Cellular |
| 147 |
Inhibition, Inducible Nitric Oxide Synthase by Metabolite CGA 265307 |
Inhibition, Inducible Nitric Oxide Synthase by Metabolite CGA 265307 |
Cellular |
| 149 |
Increase, Inflammation |
Increase, Inflammation |
Cellular |
| 151 |
Activation, Inflammatory cytokines, chemokines, cytoprotective gene pathways |
Activation, Inflammatory cytokines, chemokines, cytoprotective gene pathways |
Molecular |
| 152 |
Suppression, Inflammatory cytokines |
Suppression, Inflammatory cytokines |
Individual |
| 155 |
Inadequate DNA repair |
Inadequate DNA repair |
Cellular |
| 158 |
N/A, Interferences with SH-/selen-proteins |
N/A, Interferences with SH-/selen-proteins |
Cellular |
| 161 |
Increase, Liver and splenic hemosiderosis |
Increase, Liver and splenic hemosiderosis |
Organ |
| 164 |
Induction, Liver “Dysfunctional” Changes by CGA 330050 |
Induction, Liver “Dysfunctional” Changes by CGA 330050 |
Organ |
| 165 |
Activation, Long term AHR receptor driven direct and indirect gene expression changes |
Activation, Long term AHR receptor driven direct and indirect gene expression changes |
Cellular |
| 166 |
Decreased, Long-term potentiation (LTP) |
Decreased, Long-term potentiation (LTP) |
Organ |
| 167 |
Activation, LXR |
Activation, LXR |
Molecular |
| 168 |
Decreased, Lymphocytes |
Decreased, Lymphocytes |
Individual |
| 169 |
Disruption, Membrane integrity |
Disruption, Membrane integrity |
Cellular |
| 173 |
N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number |
N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number |
Organ |
| 176 |
Damaging, Mitochondria |
Damaging, Mitochondria |
Cellular |
| 177 |
N/A, Mitochondrial dysfunction 1 |
N/A, Mitochondrial dysfunction 1 |
Cellular |
| 178 |
Disruption, Mitochondrial electron transport chain |
Disruption, Mitochondrial electron transport chain |
Cellular |
| 179 |
Decreased, Mitochondrial fatty acid beta-oxidation |
Decreased, Mitochondrial fatty acid beta-oxidation |
Molecular |
| 183 |
Abnormal, Morphogenesis |
Abnormal, Morphogenesis |
|
| 185 |
Increase, Mutations |
Increase, Mutations |
Molecular |
| 186 |
Altered, Neuroanatomy |
Altered, Neuroanatomy |
Organ |
| 188 |
Neuroinflammation |
Neuroinflammation |
Tissue |
| 191 |
Neuronal dysfunction |
Neuronal dysfunction |
Cellular |
| 192 |
Altered, Neurophysiology |
Altered, Neurophysiology |
Organ |
| 193 |
Decreased, Nitric Oxide |
Decreased, Nitric Oxide |
Cellular |
| 195 |
Inhibition, NMDARs |
Inhibition, NMDARs |
Molecular |
| 201 |
Binding of antagonist, NMDA receptors |
Binding of antagonist, NMDA receptors |
Molecular |
| 202 |
Inhibition, Nuclear factor kappa B (NF-kB) |
Inhibition, Nuclear factor kappa B (NF-kB) |
Molecular |
| 209 |
Peptide Oxidation |
Peptide Oxidation |
Molecular |
| 210 |
N/A, Oxidative stress |
N/A, Oxidative stress |
Cellular |
| 211 |
Propagation, Oxidative stress |
Propagation, Oxidative stress |
Molecular |
| 213 |
N/A, Parent compound is converted to the reactive metabolite and forms free radicals leading to oxidation of heme iron(II) in hemoglobin to iron(III) |
N/A, Parent compound is converted to the reactive metabolite and forms free radicals leadin |
Molecular |
| 214 |
Bile accumulation, Pathological condition |
Bile accumulation, Pathological condition |
Cellular |
| 216 |
Decreased, PCK1 expression (control point for glycolysis/gluconeogenesis pathway) |
Decreased, PCK1 expression (control point for glycolysis/gluconeogenesis pathway) |
Cellular |
| 219 |
Reduction, Plasma 17beta-estradiol concentrations |
Reduction, Plasma 17beta-estradiol concentrations |
Organ |
| 220 |
Increase, Plasma vitellogenin concentrations |
Increase, Plasma vitellogenin concentrations |
Organ |
| 221 |
Reduction, Plasma vitellogenin concentrations |
Reduction, Plasma vitellogenin concentrations |
Organ |
| 222 |
Elimination of (high doses), Posterior cardinal vein |
Elimination of (high doses), Posterior cardinal vein |
|
| 227 |
Activation, PPARα |
Activation, PPARα |
Molecular |
| 228 |
peroxisome proliferator activated receptor promoter demethylation |
demethylation, PPARg promoter |
Molecular |
| 231 |
Decreased, PPAR-alpha activation |
Decreased, PPAR-alpha activation |
Molecular |
| 232 |
Decreased, PPAR-beta activation |
Decreased, PPAR-beta activation |
Molecular |
| 233 |
Decreased, PPAR-gamma activation |
Decreased, PPAR-gamma activation |
Molecular |
| 234 |
Activation, PPARα & PPARγ |
Activation, PPARα & PPARγ |
Molecular |
| 238 |
Induction, Pre-mature molting |
Induction, Pre-mature molting |
|
| 239 |
Activation, Pregnane-X receptor, NR1l2 |
Activation, Pregnane-X receptor, NR1l2 |
Molecular |
| 240 |
Feminisation or incomplete development, Primary and accessory male sex organs |
Feminisation or incomplete development, Primary and accessory male sex organs |
Organ |
| 243 |
Reduction, Prostaglandin E2 concentration |
Reduction, Prostaglandin E2 concentration |
Tissue |
| 244 |
Alkylation, Protein |
Alkylation, Protein |
Molecular |
| 245 |
Activation, PXR/SXR |
Activation, PXR/SXR |
Molecular |
| 246 |
Increase, RBC congestion in liver |
Increase, RBC congestion in liver |
Organ |
| 249 |
Production, Reactive oxygen species |
Production, Reactive oxygen species |
Tissue |
| 250 |
Damaging, Red blood cells; hemolysis |
Damaging, Red blood cells; hemolysis |
Cellular |
| 252 |
Increase, Renal pathology due to VTG deposition |
Increase, Renal pathology due to VTG deposition |
Organ |
| 253 |
N/A, Reproductive failure |
N/A, Reproductive failure |
Individual |
| 257 |
Increase, Reactive Oxygen Species production |
Increase, ROS production |
Molecular |
| 258 |
Activation, SCD-1 |
Activation, SCD-1 |
Molecular |
| 261 |
Binding, SH-/selen-proteins |
Binding, SH-/selen-proteins |
Molecular |
| 264 |
Activation, SREBP-1c |
Activation, SREBP-1c |
Molecular |
| 265 |
Activation, Stellate cells |
Activation, Stellate cells |
Cellular |
| 266 |
Decrease, Steroidogenic acute regulatory protein (STAR) |
Decrease, Steroidogenic acute regulatory protein (STAR) |
Cellular |
| 269 |
Induction, Sustained Cell Proliferation |
Induction, Sustained Cell Proliferation |
Cellular |
| 270 |
Induction, Sustained Hepatotoxicity |
Induction, Sustained Hepatotoxicity |
Individual |
| 272 |
Activation/Proliferation, T-cells |
Activation/Proliferation, T-cells |
Organ |
| 274 |
Reduction, Testosterone synthesis by ovarian theca cells |
Reduction, Testosterone synthesis by ovarian theca cells |
Cellular |
| 276 |
Up Regulation, TGFbeta1 expression |
Up Regulation, TGFbeta1 expression |
Cellular |
| 277 |
Thyroid hormone synthesis, Decreased |
TH synthesis, Decreased |
Cellular |
| 279 |
Thyroperoxidase, Inhibition |
Thyroperoxidase, Inhibition |
Molecular |
| 280 |
Thyroxine (T4) in neuronal tissue, Decreased |
T4 in neuronal tissue, Decreased |
Organ |
| 281 |
Thyroxine (T4) in serum, Decreased |
T4 in serum, Decreased |
Tissue |
| 285 |
Reduction, Vitellogenin synthesis in liver |
Reduction, Vitellogenin synthesis in liver |
Tissue |
| 286 |
Altered, Transcription of genes by AR |
Altered, Transcription of genes by AR |
Cellular |
| 288 |
Activation of specific nuclear receptors, Transcriptional change |
Activation of specific nuclear receptors, Transcriptional change |
Cellular |
| 289 |
Decrease, Translocator protein (TSPO) |
Decrease, Translocator protein (TSPO) |
Cellular |
| 291 |
Accumulation, Triglyceride |
Accumulation, Triglyceride |
Cellular |
| 294 |
N/A, Unknown |
N/A, Unknown |
Molecular |
| 295 |
Induction, Upregulation of glucuronyltransferase activity |
Induction, Upregulation of glucuronyltransferase activity |
Molecular |
| 298 |
Insufficiency, Vascular |
Insufficiency, Vascular |
Molecular |
| 301 |
Binding, VEGF-A |
Binding, VEGF-A |
|
| 302 |
Production, VEGF-A |
Production, VEGF-A |
|
| 304 |
Decreased, VegfR2 |
Decreased, VegfR2 |
|
| 305 |
Inhibition, VegfR2 |
Inhibition, VegfR2 |
Molecular |
| 307 |
Increase, Vitellogenin synthesis in liver |
Increase, Vitellogenin synthesis in liver |
Tissue |
| 309 |
Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development |
Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development |
Cellular |
| 310 |
Alteration, Wnt pathway |
Alteration, Wnt pathway |
Cellular |
| 312 |
N/A, Allergic contact dermatitis on challenge |
N/A, Allergic contact dermatitis on challenge |
Individual |
| 313 |
Increase, Allergic Respiratory Hypersensitivity Response |
Increase, Allergic Respiratory Hypersensitivity Response |
Organ |
| 315 |
Decreased, Body length |
Decreased, Body length |
|
| 317 |
Altered, Cardiovascular development/function |
Altered, Cardiovascular development/function |
Organ |
| 319 |
Loss, Cochlear function |
Loss, Cochlear function |
Organ |
| 320 |
Increase, Curved body axis |
Increase, Curved body axis |
|
| 321 |
N/A, Cyanosis occurs |
N/A, Cyanosis occurs |
Individual |
| 323 |
Increased, Disease susceptibility |
Increased, Disease susceptibility |
Individual |
| 327 |
Accumulation, Fatty acid |
Accumulation, Fatty acid |
Organ |
| 328 |
Decrease, Fecundity |
Decrease, Fecundity |
Individual |
| 330 |
Decrease, Fertility |
Decrease, Fertility |
Individual |
| 334 |
Promotion, Hepatocelluar carcinoma |
Promotion, Hepatocelluar carcinoma |
Individual |
| 336 |
Increase, Heritable mutations in offspring |
Increase, Heritable mutations in offspring |
Individual |
| 337 |
N/A, Impairment of reproductive capacity |
N/A, Impairment of reproductive capacity |
Individual |
| 339 |
Altered, Larval development |
Altered, Larval development |
Individual |
| 341 |
Impairment, Learning and memory |
Impairment, Learning and memory |
Individual |
| 342 |
Increased, Lethality |
Increased, Lethality |
|
| 344 |
N/A, Liver fibrosis |
N/A, Liver fibrosis |
Organ |
| 345 |
N/A, Liver Steatosis |
N/A, Liver Steatosis |
Organ |
| 347 |
Formation, Liver tumor |
Formation, Liver tumor |
Individual |
| 348 |
Malformation, Male reproductive tract |
Malformation, Male reproductive tract |
Organ |
| 350 |
Increase, Mortality |
Increase, Mortality |
Individual |
| 351 |
Increased Mortality |
Increased Mortality |
Population |
| 352 |
N/A, Neurodegeneration |
N/A, Neurodegeneration |
Tissue |
| 356 |
Increased, Oxidative damage |
Increased, Oxidative damage |
Individual |
| 357 |
Cholestasis, Pathology |
Cholestasis, Pathology |
Individual |
| 358 |
Increase, Pericardial edema |
Increase, Pericardial edema |
Organ |
| 360 |
Decrease, Population growth rate |
Decrease, Population growth rate |
Population |
| 361 |
Decline, Population |
Decline, Population |
Population |
| 363 |
Altered, Reproductive behaviour |
Altered, Reproductive behaviour |
Individual |
| 364 |
Impaired development of, Reproductive organs |
Impaired development of, Reproductive organs |
Individual |
| 366 |
Increased, Structural malformations |
Increased, Structural malformations |
|
| 369 |
Uroporphyria |
Uroporphyria |
Individual |
| 373 |
Formation, Pro-mutagenic DNA Adducts |
Formation, Pro-mutagenic DNA Adducts |
Molecular |
| 376 |
Increased, Induced Mutations in Critical Genes |
Increased, Induced Mutations in Critical Genes |
Cellular |
| 377 |
Increased, Proliferation/Clonal Expansion of Mutant Cells (Pre-Neoplastic Lesions/Altered Hepatic Foci (AHF)) |
Increased, Proliferation/Clonal Expansion of Mutant Cells (Pre-Neoplastic Lesions/Altered H |
|
| 378 |
Tumorigenesis, Hepatocellular carcinoma |
Tumorigenesis, Hepatocellular carcinoma |
Individual |
| 380 |
Activation, Pre-MIE: Metabolism of AFB1 |
Activation, Pre-MIE: Metabolism of AFB1 |
Molecular |
| 381 |
Reduced levels of BDNF |
BDNF, Reduced |
Molecular |
| 382 |
Aberrant, Dendritic morphology |
Aberrant, Dendritic morphology |
Cellular |
| 383 |
Reduced, Presynaptic release of glutamate |
Reduced, Presynaptic release of glutamate |
Molecular |
| 384 |
Increased, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci |
Increased, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci |
|
| 385 |
Decrease of synaptogenesis |
Synaptogenesis, Decreased |
Cellular |
| 386 |
Decrease of neuronal network function |
Neuronal network function, Decreased |
Organ |
| 387 |
Binding of agonist, NMDARs |
Binding of agonist, NMDARs |
Molecular |
| 388 |
Overactivation, NMDARs |
Overactivation, NMDARs |
Cellular |
| 389 |
Increased, Intracellular Calcium overload |
Increased, Intracellular Calcium overload |
Cellular |
| 396 |
Covalent Binding, Protein |
Covalent Binding, Protein |
Molecular |
| 397 |
Response, Keratinocytes |
Response, Keratinocytes |
Cellular |
| 398 |
Activation, Dendritic Cells |
Activation, Dendritic Cells |
Cellular |
| 401 |
Increase, Biliary excretion TH glucuronide |
Increase, Biliary excretion TH glucuronide |
Organ |
| 402 |
Cognitive Function, Decreased |
Cognitive Function, Decreased |
Individual |
| 403 |
Suppression, Immune system |
Suppression, Immune system |
Individual |
| 405 |
irregularities, ovarian cycle |
irregularities, ovarian cycle |
Individual |
| 406 |
impaired, Fertility |
impaired, Fertility |
Individual |
| 408 |
reduction in ovarian granulosa cells, Aromatase (Cyp19a1) |
reduction in ovarian granulosa cells, Aromatase (Cyp19a1) |
Cellular |
| 409 |
Metabolism of AFB1, Production of Reactive Electrophiles |
Metabolism of AFB1, Production of Reactive Electrophiles |
Molecular |
| 413 |
Reduction, Testosterone synthesis in Leydig cells |
Reduction, Testosterone synthesis in Leydig cells |
Cellular |
| 414 |
Increase, Luteinizing hormone (LH) |
Increase, Luteinizing hormone (LH) |
Cellular |
| 415 |
Hyperplasia, Leydig cell |
Hyperplasia, Leydig cell |
Cellular |
| 416 |
Increase proliferation, Leydig cell |
Increase proliferation, Leydig cell |
Cellular |
| 417 |
skewed, sex ratio |
skewed, sex ratio |
Population |
| 418 |
Increased, Vitellogenin synthesis |
Increased, Vitellogenin synthesis |
Cellular |
| 419 |
Increased, renal vitellogenin deposition |
Increased, renal vitellogenin deposition |
Organ |
| 421 |
Increased, glomerular rupture and renal hemorrhaging |
Increased, glomerular rupture and renal hemorrhaging |
Organ |
| 422 |
Increased, nephropathy |
Increased, nephropathy |
Individual |
| 423 |
Increased, Clonal Expansion / Cell Proliferation to Form Pre-Neoplastic Altered Hepatic Foci |
Increased, Clonal Expansion / Cell Proliferation to Form Pre-Neoplastic Altered Hepatic Foc |
|
| 424 |
Inhibition, Na+/I- symporter (NIS) |
Inhibition, Na+/I- symporter (NIS) |
Molecular |
| 425 |
Decrease of Thyroidal iodide |
Thyroidal Iodide, Decreased |
Cellular |
| 427 |
Down Regulation, K-Cl co-transporter 2 (KCC2) |
Down Regulation, K-Cl co-transporter 2 (KCC2) |
Cellular |
| 428 |
Delay, Developmental GABA shift |
Delay, Developmental GABA shift |
Cellular |
| 429 |
Cellular Proliferation and Clonal Expansion of Mutant Cells (Pre-neoplastic Foci), Alteration of cellular growth homeostasis |
Cellular Proliferation and Clonal Expansion of Mutant Cells (Pre-neoplastic Foci), Alterati |
|
| 442 |
Decreased, Population trajectory |
Decreased, Population trajectory |
Population |
| 444 |
Increased, Atrioventricular block and bradycardia |
Increased, Atrioventricular block and bradycardia |
Organ |
| 445 |
Respiratory distress/arrest |
Respiratory distress/arrest |
Organ |
| 446 |
Reduction, fetal/adult testosterone |
Reduction of testosterone |
Tissue |
| 447 |
Reduction, Cholesterol transport in mitochondria |
Reduction, Cholesterol transport in mitochondria |
Cellular |
| 450 |
Suppression, VLDL secretion |
Suppression, VLDL secretion |
Cellular |
| 451 |
Inhibition, Mitochondrial fatty acid beta-oxidation |
Inhibition, Mitochondrial fatty acid beta-oxidation |
Molecular |
| 454 |
Increased, Triglyceride formation |
Increased, Triglyceride formation |
Cellular |
| 455 |
Accumulation, Liver lipid |
Accumulation, Liver lipid |
Organ |
| 456 |
Suppression, Constitutive androstane receptor, NR1l3 |
Suppression, Constitutive androstane receptor, NR1l3 |
Molecular |
| 457 |
Activation, SREBF1 |
Activation, SREBF1 |
Molecular |
| 458 |
Increased, De Novo FA synthesis |
Increased, De Novo FA synthesis |
Cellular |
| 459 |
Increased, Liver Steatosis |
Increased, Liver Steatosis |
Organ |
| 460 |
Increased, Fatty acid uptake |
Increased, Fatty acid uptake |
Cellular |
| 461 |
Suppression, HNF4alpha |
Suppression, HNF4alpha |
Molecular |
| 462 |
Up Regulation, SCD-1 |
Up Regulation, SCD-1 |
Molecular |
| 463 |
Up Regulation, FAS |
Up Regulation, FAS |
Molecular |
| 465 |
Increased, FA Influx |
Increased, FA Influx |
Cellular |
| 466 |
Up Regulation, LDLR (low density lipoprotein receptor) |
Up Regulation, LDLR (low density lipoprotein receptor) |
Molecular |
| 467 |
Increased, LDL uptake |
Increased, LDL uptake |
Cellular |
| 468 |
Inhibition, PPAR alpha |
Inhibition, PPAR alpha |
Molecular |
| 470 |
Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1) |
Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1) |
Molecular |
| 471 |
Inhibition, FoxA2 |
Inhibition, FoxA2 |
Molecular |
| 472 |
Down Regulation, CPT1A |
Down Regulation, CPT1A |
Molecular |
| 474 |
Down Regulation, HMGCS2 |
Down Regulation, HMGCS2 |
Molecular |
| 477 |
Decreased, Ketogenesis |
Decreased, Ketogenesis |
Cellular |
| 478 |
Activation, NRF2 |
Activation, NRF2 |
Molecular |
| 479 |
Activation, NR1H4 |
Activation, NR1H4 |
Molecular |
| 480 |
Activation, SHP |
Activation, SHP |
Molecular |
| 482 |
Decreased, DHB4/HSD17B4 |
Decreased, DHB4/HSD17B4 |
Molecular |
| 483 |
Activation, LXR alpha |
Activation, LXR alpha |
Molecular |
| 484 |
Activation, AKT2 |
Activation, AKT2 |
Molecular |
| 486 |
systemic inflammation leading to hepatic steatosis |
inflammation |
Organ |
| 488 |
Decrease, Ovulation |
Decrease, Ovulation |
Organ |
| 491 |
Clonal Expansion/Cell Proliferation, to form Altered Hepatic Foci (AHF) |
Clonal Expansion/Cell Proliferation, to form Altered Hepatic Foci (AHF) |
Organ |
| 493 |
Increased, Insufficient repair or mis-repair of pro-mutagenic DNA adducts |
Increased, Insufficient repair or mis-repair of pro-mutagenic DNA adducts |
Molecular |
| 494 |
Glucocorticoid Receptor Agonist, Activation |
GR Agonist, Activation |
Molecular |
| 495 |
Repressed expression of steroidogenic enzymes |
Repressed expression of steroidogenic enzymes |
Cellular |
| 496 |
Increased apoptosis, decreased fetal/adult Leydig Cells |
Decreased Leydig Cells |
Cellular |
| 505 |
Decreased sperm quantity / quality in the adult, Decreased fertility |
Decreased sperm quantity / quality in the adult, Decreased fertility |
Individual |
| 520 |
Decreased sperm quantity or quality in the adult, Decreased fertility |
Decreased sperm quantity or quality in the adult, Decreased fertility |
Individual |
| 525 |
Apoptosis of adult Leydig cells, Decreased testosterone by adult Leydig cells |
Apoptosis of adult Leydig cells, Decreased testosterone by adult Leydig cells |
Cellular |
| 526 |
Inhibition, Inhibition of Dopamine-beta-hydroxylase |
Inhibition, Inhibition of Dopamine-beta-hydroxylase |
Molecular |
| 527 |
Decreased, Decreased fecundity |
Decreased, Decreased fecundity |
Individual |
| 528 |
Decreased, Synthesis of NE |
Decreased, Synthesis of NE |
Cellular |
| 529 |
Decreased, GnRH cfos activity |
Decreased, GnRH cfos activity |
Molecular |
| 530 |
Decreased, GnRH pulsatility/release |
Decreased, GnRH pulsatility/release |
Cellular |
| 531 |
Decreased, LH Surge |
Decreased, LH Surge |
Cellular |
| 532 |
Delayed, Ovulation |
Delayed, Ovulation |
Individual |
| 533 |
Decreased, Cortical granule release/distribution upon fertilization |
Decreased, Cortical granule release/distribution upon fertilization |
Cellular |
| 534 |
Altered, Formation of cortical envelope |
Altered, Formation of cortical envelope |
Cellular |
| 535 |
Abnormal, Sperm penetration (polyspermy) |
Abnormal, Sperm penetration (polyspermy) |
Cellular |
| 536 |
Altered, Chromosome number (polyploid) zygote |
Altered, Chromosome number (polyploid) zygote |
Cellular |
| 540 |
Decreased testosterone by the fetal Leydig cells, Dysgensis of fetal Leydig cells |
Decreased testosterone by the fetal Leydig cells, Dysgensis of fetal Leydig cells |
Organ |
| 541 |
Decreased testosterone by the fetal Leydig cells, Decreased COUP-TFII stem Leydig cells |
Decreased testosterone by the fetal Leydig cells, Decreased COUP-TFII stem Leydig cells |
Cellular |
| 543 |
Decreased fertility in the adult, Decreased sperm quantity and/or quality in the adult testis |
Decreased fertility in the adult, Decreased sperm quantity and/or quality in the adult test |
Individual |
| 559 |
Activation, Nicotinic acetylcholine receptor |
Activation, Nicotinic acetylcholine receptor |
Molecular |
| 560 |
Abnormal, Foraging activity and behavior |
Abnormal, Foraging activity and behavior |
Individual |
| 561 |
Reduced, Food storage |
Reduced, Food storage |
Population |
| 563 |
Death/Failure, Colony |
Death/Failure, Colony |
Population |
| 564 |
Abnormal, Roll change within caste |
Abnormal, Roll change within caste |
Population |
| 565 |
Reduced, Brood care |
Reduced, Brood care |
Population |
| 566 |
impaired, Larval development |
impaired, Larval development |
Population |
| 568 |
impaired, Hive thermoregulation |
impaired, Hive thermoregulation |
Population |
| 570 |
Accumulation, Damaged mitochondrial DNA |
Accumulation, Damaged mitochondrial DNA |
Cellular |
| 571 |
Accelerated, Aging |
Accelerated, Aging |
Individual |
| 572 |
Decrease, Number of worker bees |
Decrease, Number of worker bees |
Population |
| 573 |
Increase, Energetic demands and therefore metabolic stress |
Increase, Energetic demands and therefore metabolic stress |
Individual |
| 574 |
Increased, Appetite and hunger |
Increased, Appetite and hunger |
Individual |
| 576 |
Increased, Viral susceptibility |
Increased, Viral susceptibility |
Individual |
| 577 |
impaired, Development |
impaired, Development |
Individual |
| 578 |
Decreased, Glucose oxidase enzyme activity |
Decreased, Glucose oxidase enzyme activity |
Molecular |
| 579 |
Decreased, Hydrogen peroxide production |
Decreased, Hydrogen peroxide production |
Molecular |
| 580 |
Reduced, Antiseptic incorporated in food |
Reduced, Antiseptic incorporated in food |
Population |
| 583 |
impaired, Thoracic shivering |
impaired, Thoracic shivering |
Individual |
| 584 |
Inhibition, sodium channel |
Inhibition, sodium channel |
Molecular |
| 585 |
Decreased, Sodium conductance 1 |
Decreased, Sodium conductance 1 |
Cellular |
| 586 |
Reduced, swimming speed |
Reduced, swimming speed |
Individual |
| 587 |
Reduced, feeding 1 |
Reduced, feeding 1 |
Individual |
| 588 |
Increased, predation |
Increased, predation |
Population |
| 590 |
N/A, hypoxia |
N/A, hypoxia |
Tissue |
| 591 |
Increased, amputations |
Increased, amputations |
Individual |
| 592 |
Reduced, survival |
Reduced, survival |
Population |
| 593 |
Inhibition, Ether-a-go-go (ERG) voltage-gated potassium channel |
Inhibition, Ether-a-go-go (ERG) voltage-gated potassium channel |
Molecular |
| 598 |
modulation, sodium channel |
modulation, sodium channel |
Molecular |
| 599 |
prolonged, Depolarization of neuronal membrane |
prolonged, Depolarization of neuronal membrane |
Cellular |
| 600 |
Overactivation, Neuronotransmitter release |
Overactivation, Neuronotransmitter release |
Molecular |
| 601 |
Overactivation, muscle contraction |
Overactivation, muscle contraction |
Tissue |
| 602 |
Increased, Ataxia, paralysis, or hyperactivity |
Increased, Ataxia, paralysis, or hyperactivity |
Organ |
| 613 |
Occurrence, Epileptic seizure |
Occurrence, Epileptic seizure |
Individual |
| 616 |
Occurrence, A paroxysmal depolarizing shift |
Occurrence, A paroxysmal depolarizing shift |
Tissue |
| 618 |
Decreased, Neuronal network function in adult brain |
Decreased, Neuronal network function in adult brain |
Organ |
| 619 |
Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) |
Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) |
Molecular |
| 620 |
Increased, serotonin (5-HT) 1 1 |
Increased, serotonin (5-HT) 1 |
Molecular |
| 621 |
Increase, cilia movement |
Increase, cilia movement |
Tissue |
| 622 |
Increased, locomotion |
Increased, locomotion |
Individual |
| 623 |
Increase, predation |
Increase, predation |
Population |
| 624 |
Increased, foot detachment |
Increased, foot detachment |
Individual |
| 625 |
Increased, muscular waves in foot |
Increased, muscular waves in foot |
Organ |
| 626 |
Increased, serotonin (5-HT) |
Increased, serotonin (5-HT) |
Cellular |
| 627 |
Decreased, anxiety |
Decreased, anxiety |
Individual |
| 629 |
Decreased, sheltering |
Decreased, sheltering |
Individual |
| 633 |
Decrease, histaminergic neuron excitation |
Decrease, histaminergic neuron excitation |
Cellular |
| 634 |
N/A, sedation |
N/A, sedation |
Individual |
| 635 |
Decreased, locomotion |
Decreased, locomotion |
Individual |
| 636 |
Decreased, survival |
Decreased, survival |
Population |
| 637 |
impaired, Learning and memory |
impaired, Learning and memory |
Individual |
| 638 |
Antagonism, Histamine Receptor (H2) |
Antagonism, Histamine Receptor (H2) |
Molecular |
| 640 |
Decreased steroidogenesis, Proteomic alterations in the adult Leydig cell |
Decreased steroidogenesis, Proteomic alterations in the adult Leydig cell |
Molecular |
| 642 |
Decreased Cholesterol, Decreased De Novo Biosynthesis of Choleseterol |
Decreased Cholesterol, Decreased De Novo Biosynthesis of Choleseterol |
Molecular |
| 643 |
Decreased Cholesterol, Decreased Uptake of Lipoproteins |
Decreased Cholesterol, Decreased Uptake of Lipoproteins |
Molecular |
| 644 |
Decreased Cholesterol, Decreased Transport of Cholesterol to the Inner Mitochondrial Membrane |
Decreased Cholesterol, Decreased Transport of Cholesterol to the Inner Mitochondrial Membra |
Molecular |
| 645 |
Decreased Cholesterol, Decreased Testosterone Production by Adult Leydig Cells |
Decreased Cholesterol, Decreased Testosterone Production by Adult Leydig Cells |
Cellular |
| 646 |
Decreased Cholesterol, Decreased sperm quantity and/or quality in the adult testis |
Decreased Cholesterol, Decreased sperm quantity and/or quality in the adult testis |
Organ |
| 647 |
Decreased steroidogenesis, Decreased Activity of Steroidogenic Enzymes in Adult Leydig cells |
Decreased steroidogenesis, Decreased Activity of Steroidogenic Enzymes in Adult Leydig cell |
Cellular |
| 648 |
Decreased steroidogenesis, Increased Apoptosis of Adult Leydig Cells |
Decreased steroidogenesis, Increased Apoptosis of Adult Leydig Cells |
Tissue |
| 649 |
Decreased steroidogenesis, Alterations in the Leydig Cell Cytoskeleton |
Decreased steroidogenesis, Alterations in the Leydig Cell Cytoskeleton |
Tissue |
| 650 |
Stimulation of adult Leydig cells via the Adrenal Corticosterone, Increased Glucocorticoid |
Stimulation of adult Leydig cells via the Adrenal Corticosterone, Increased Glucocorticoid |
Molecular |
| 651 |
Glucocorticoid Receptor mediated alterations in steriodogenic enzymes, Decreased testosterone by adult Leydig cells |
Glucocorticoid Receptor mediated alterations in steriodogenic enzymes, Decreased testostero |
Cellular |
| 652 |
Direct effects of Corticosterone on steroidogenesis, Decreased testosterone by adult Leydig cells |
Direct effects of Corticosterone on steroidogenesis, Decreased testosterone by adult Leydig |
Cellular |
| 653 |
Decreased testosterone by the fetal Leydig cells, Increased corticosterone |
Decreased testosterone by the fetal Leydig cells, Increased corticosterone |
Cellular |
| 654 |
Decreased testosterone by the fetal Leydig cells, Activation by other glucocorticoid receptor agonists |
Decreased testosterone by the fetal Leydig cells, Activation by other glucocorticoid recept |
Cellular |
| 655 |
Decreased testosterone by the fetal Leydig cells, Increased COUP-TFII in fetal Leydig cells |
Decreased testosterone by the fetal Leydig cells, Increased COUP-TFII in fetal Leydig cells |
Cellular |
| 656 |
Decreased number and function of adult Leydig cells, Decreased COUP-TFII stem Leydig cells |
Decreased number and function of adult Leydig cells, Decreased COUP-TFII stem Leydig cells |
Cellular |
| 657 |
Decreased testosterone by the fetal Leydig cells, Dysgenesis of fetal Leydig cells |
Decreased testosterone by the fetal Leydig cells, Dysgenesis of fetal Leydig cells |
Organ |
| 658 |
Decreased testosterone by the fetal Leydig cells, Increased estradiol |
Decreased testosterone by the fetal Leydig cells, Increased estradiol |
Cellular |
| 659 |
Decreased testosterone by the fetal Leydig cells, Activation by other estradiol agonists |
Decreased testosterone by the fetal Leydig cells, Activation by other estradiol agonists |
Cellular |
| 660 |
decreased testosterone by fetal Leydig cells, Dysgenesis of fetal Leydig cells |
decreased testosterone by fetal Leydig cells, Dysgenesis of fetal Leydig cells |
Organ |
| 661 |
Decreased testosterone by the fetal Leydig cells, Alterations in the fetal testis proteome |
Decreased testosterone by the fetal Leydig cells, Alterations in the fetal testis proteome |
Molecular |
| 662 |
Decreased testosterone by the fetal Leydig cells, Hypermethylation in the fetal testis |
Decreased testosterone by the fetal Leydig cells, Hypermethylation in the fetal testis |
Molecular |
| 663 |
Desensitization, Nicotinic acetylcholine receptor |
Desensitization, Nicotinic acetylcholine receptor |
Molecular |
| 664 |
Overwhelmed, Mitochondrial DNA repair mechanisms |
Overwhelmed, Mitochondrial DNA repair mechanisms |
Cellular |
| 667 |
Binding at picrotoxin site, iGABAR chloride channel |
Binding at picrotoxin site, iGABAR chloride channel |
Molecular |
| 669 |
Reduction, Neuronal synaptic inhibition |
Reduction, Neuronal synaptic inhibition |
Cellular |
| 671 |
Reduced, Prostaglandin F2alpha concentration, plasma |
Reduced, Prostaglandin F2alpha concentration, plasma |
Individual |
| 672 |
Reduced, Prostaglandin F2alpha synthesis, ovary |
Reduced, Prostaglandin F2alpha synthesis, ovary |
Organ |
| 673 |
Reduced, Spawning behavior |
Reduced, Spawning behavior |
Individual |
| 674 |
Reduced, Ability to attract spawning mates |
Reduced, Ability to attract spawning mates |
Individual |
| 675 |
Reduced, Reproductive Success |
Reduced, Reproductive Success |
Individual |
| 678 |
Reduced, Pheromone release |
Reduced, Pheromone release |
Individual |
| 679 |
Decline, Population trajectory |
Decline, Population trajectory |
Population |
| 681 |
Decreased, Prostaglandin F2alpha synthesis, ovary |
Decreased, Prostaglandin F2alpha synthesis, ovary |
Organ |
| 682 |
Generation, Amplified excitatory postsynaptic potential (EPSP) |
Generation, Amplified excitatory postsynaptic potential (EPSP) |
Cellular |
| 685 |
Reduced, Prostaglandins, ovary |
Reduced, Prostaglandins, ovary |
Organ |
| 687 |
Reduced, Prostaglandin E2 concentration, hypothalamus |
Reduced, Prostaglandin E2 concentration, hypothalamus |
Tissue |
| 689 |
Reduced, Gonadotropin releasing hormone, hypothalamus |
Reduced, Gonadotropin releasing hormone, hypothalamus |
Tissue |
| 690 |
Reduced, Luteinizing hormone (LH), plasma |
Reduced, Luteinizing hormone (LH), plasma |
Tissue |
| 691 |
Reduced, Maturation inducing steroid, plasma |
Reduced, Maturation inducing steroid, plasma |
Tissue |
| 692 |
Reduced, Maturation inducing steroid receptor signalling, oocyte |
Reduced, Maturation inducing steroid receptor signalling, oocyte |
Tissue |
| 693 |
Increased, cyclic adenosine monophosphate |
Increased, cyclic adenosine monophosphate |
Tissue |
| 694 |
Reduced, Meiotic prophase I/metaphase I transition, oocyte |
Reduced, Meiotic prophase I/metaphase I transition, oocyte |
Cellular |
| 695 |
Upregulated, Spindle assembly checkpoint protein Mad2-oocyte |
Upregulated, Spindle assembly checkpoint protein Mad2-oocyte |
Molecular |
| 696 |
Increased, Chromosome misseggregation |
Increased, Chromosome misseggregation |
Cellular |
| 697 |
impaired, ion channels |
impaired, ion channels |
Cellular |
| 698 |
Altered, Action Potential |
Altered, Action Potential |
Cellular |
| 699 |
Increased, cardiac arrthymia |
Increased, cardiac arrthymia |
Organ |
| 708 |
Increased, Accumulation of alpha2u microglobulin (proximal tubular epithelium) |
Increased, Accumulation of alpha2u microglobulin (proximal tubular epithelium) |
Tissue |
| 709 |
Increase, Cytotoxicity (renal tubular cell) |
Increase, Cytotoxicity (renal tubular cell) |
Cellular |
| 710 |
Increase, Regenerative cell proliferation (tubular epithelial cells) |
Increase, Regenerative cell proliferation (tubular epithelial cells) |
Cellular |
| 713 |
Increase, Adenomas/carcinomas (renal tubular) |
Increase, Adenomas/carcinomas (renal tubular) |
Tissue |
| 714 |
Increased, Binding of chemicals to 2u (serum) |
Increased, Binding of chemicals to 2u (serum) |
Molecular |
| 715 |
Activation, Constitutive androstane receptor |
Activation, Constitutive androstane receptor |
Molecular |
| 716 |
Increase, cell proliferation (hepatocytes) |
Increase, cell proliferation (hepatocytes) |
Cellular |
| 718 |
Binding, Tubulin |
Binding, Tubulin |
Molecular |
| 719 |
Increase, hepatocellular adenomas and carcinomas |
Increase, hepatocellular adenomas and carcinomas |
Tissue |
| 720 |
Disruption, Microtubule dynamics |
Disruption, Microtubule dynamics |
Molecular |
| 721 |
Disorganization, Meiotic Spindle |
Disorganization, Meiotic Spindle |
Cellular |
| 723 |
Altered, Chromosome number |
Altered, Chromosome number |
Cellular |
| 724 |
Inhibition, Pyruvate dehydrogenase kinase (PDK) enzyme |
Inhibition, Pyruvate dehydrogenase kinase (PDK) enzyme |
Cellular |
| 726 |
Increased, Induction of pyruvate dehydrogenase (PDH) |
Increased, Induction of pyruvate dehydrogenase (PDH) |
Molecular |
| 728 |
Increase, Aneuploid offspring |
Increase, Aneuploid offspring |
Individual |
| 733 |
Increase, Necrosis (terminal bronchiolar cells) |
Increase, Necrosis (terminal bronchiolar cells) |
Cellular |
| 734 |
Increase, Regenerative cell proliferation (terminal bronchiolar epithelial cells) |
Increase, Regenerative cell proliferation (terminal bronchiolar epithelial cells) |
Cellular |
| 735 |
Increase, Hyperplasia (terminal bronchiolar cells) |
Increase, Hyperplasia (terminal bronchiolar cells) |
Cellular |
| 736 |
Increase, Adenomas/carcinomas (bronchioloalveolar) |
Increase, Adenomas/carcinomas (bronchioloalveolar) |
Tissue |
| 737 |
Decreased, Uptake of inorganic iodide |
Decreased, Uptake of inorganic iodide |
Cellular |
| 739 |
Increase, Hypertrophy and proliferation (follicular cell) |
Increase, Hypertrophy and proliferation (follicular cell) |
Cellular |
| 740 |
Increase, Hyperplasia (follicular cells) |
Increase, Hyperplasia (follicular cells) |
Cellular |
| 741 |
Increase, Adenomas/carcinomas (follicular cell) |
Increase, Adenomas/carcinomas (follicular cell) |
Tissue |
| 742 |
Decreased, Androgen receptor activity |
Decreased, Androgen receptor activity |
Molecular |
| 743 |
Decreased, Testosterone binding to androgen receptor (hypothalamus) |
Decreased, Testosterone binding to androgen receptor (hypothalamus) |
Molecular |
| 744 |
Increase, Hyperplasia (Leydig cells) |
Increase, Hyperplasia (Leydig cells) |
Cellular |
| 745 |
Increase, Leydig cell tumors |
Increase, Leydig cell tumors |
Cellular |
| 746 |
Increase, Dopaminergic activity |
Increase, Dopaminergic activity |
Cellular |
| 747 |
Decreased, Prolactin |
Decreased, Prolactin |
Tissue |
| 748 |
Increased, Estrogen receptor (ER) activity |
Increased, Estrogen receptor (ER) activity |
Molecular |
| 749 |
Decreased, Progesterone from corpus luteum |
Decreased, Progesterone from corpus luteum |
Tissue |
| 752 |
Altered, Meiotic chromosome dynamics |
Altered, Meiotic chromosome dynamics |
Cellular |
| 753 |
Increase, Thyroid-stimulating hormone (TSH) |
Increase, Thyroid-stimulating hormone (TSH) |
Tissue |
| 754 |
Increased, Luteinizing hormone (LH) |
Increased, Luteinizing hormone (LH) |
Tissue |
| 756 |
Hippocampal gene expression, Altered |
Hippocampal gene expression, Altered |
Tissue |
| 757 |
Hippocampal anatomy, Altered |
Hippocampal anatomy, Altered |
Tissue |
| 758 |
Hippocampal Physiology, Altered |
Hippocampal Physiology, Altered |
Tissue |
| 759 |
Increased, Kidney Failure |
Increased, Kidney Failure |
Population |
| 760 |
Activation, Glutamate-gated chloride channel |
Activation, Glutamate-gated chloride channel |
Molecular |
| 761 |
Increased, Chloride conductance |
Increased, Chloride conductance |
Cellular |
| 762 |
Activation, ionotropic GABA Receptor chloride channel |
Activation, ionotropic GABA Receptor chloride channel |
Molecular |
| 763 |
hyperpolarisation, neuron |
hyperpolarisation, neuron |
Cellular |
| 764 |
N/A, Ataxia, paralysis, or hyperactivity |
N/A, Ataxia, paralysis, or hyperactivity |
Organ |
| 765 |
Decreased, population 1 |
Decreased, population 1 |
Population |
| 766 |
Inhibition, 4-hydroxyphenyl-pyruvate dioxygenase (HPPD) enzyme |
Inhibition, 4-hydroxyphenyl-pyruvate dioxygenase (HPPD) enzyme |
Molecular |
| 767 |
Increase, Hyperplasia (renal tubular cells) |
Increase, Hyperplasia (renal tubular cells) |
Cellular |
| 768 |
Increase, Cytotoxicity |
Increase, Cytotoxicity |
Cellular |
| 769 |
Increase, Oxidative metabolism |
Increase, Oxidative metabolism |
Cellular |
| 770 |
Increase, Cytotoxicity (club cells) |
Increase, Cytotoxicity (club cells) |
Cellular |
| 771 |
Decrease, Serum thyroid hormone (T4/T3) |
Decrease, Serum thyroid hormone (T4/T3) |
Tissue |
| 772 |
Increase, Hyperplasia (glandular epithelial cells of endometrium) |
Increase, Hyperplasia (glandular epithelial cells of endometrium) |
Cellular |
| 773 |
Increase, Endometrial adenocarcinomas |
Increase, Endometrial adenocarcinomas |
Tissue |
| 774 |
Increase, Preneoplastic foci (hepatocytes) |
Increase, Preneoplastic foci (hepatocytes) |
Cellular |
| 775 |
Increased, Plasma tyrosine |
Increased, Plasma tyrosine |
Tissue |
| 776 |
Increase, Cytotoxicity (corneal cells) |
Increase, Cytotoxicity (corneal cells) |
Cellular |
| 777 |
Increase, Inflammation (corneal cells) |
Increase, Inflammation (corneal cells) |
Cellular |
| 778 |
Increase, Regenerative cell proliferation (corneal cells) |
Increase, Regenerative cell proliferation (corneal cells) |
Cellular |
| 779 |
Increase, Papillomas/carcinomas (squamous cells) |
Increase, Papillomas/carcinomas (squamous cells) |
Cellular |
| 780 |
Increase, Cytotoxicity (epithelial cells) |
Increase, Cytotoxicity (epithelial cells) |
Cellular |
| 781 |
Increase, Regenerative cell proliferation (forestomach epithelial cells) |
Increase, Regenerative cell proliferation (forestomach epithelial cells) |
Cellular |
| 782 |
Increase, Hyperplasia (forestomach epithelial cells) |
Increase, Hyperplasia (forestomach epithelial cells) |
Cellular |
| 783 |
Increase, Cytotoxicity (tubular epithelial cells) |
Increase, Cytotoxicity (tubular epithelial cells) |
Cellular |
| 784 |
Increase, Hyperplasia (tubular epithelial cells) |
Increase, Hyperplasia (tubular epithelial cells) |
Cellular |
| 785 |
Activation, Androgen receptor |
Activation, Androgen receptor |
Molecular |
| 786 |
Increase, Cytotoxicity (hepatocytes) |
Increase, Cytotoxicity (hepatocytes) |
Cellular |
| 787 |
Increase, Regenerative cell proliferation (hepatocytes) |
Increase, Regenerative cell proliferation (hepatocytes) |
Cellular |
| 788 |
Decrease, Incorporation of active iodide into iodotyrosines |
Decrease, Incorporation of active iodide into iodotyrosines |
Cellular |
| 790 |
Inhibition, 5α-reductase activity |
Inhibition, 5α-reductase activity |
Cellular |
| 791 |
Increased, Leutinizing hormone (LH) |
Increased, Leutinizing hormone (LH) |
Tissue |
| 792 |
Decrease, Bioactivation of testosterone |
Decrease, Bioactivation of testosterone |
Tissue |
| 793 |
Increase, Urinary bladder calculi |
Increase, Urinary bladder calculi |
Organ |
| 794 |
Increase, Cytotoxicity (urothelial cells) |
Increase, Cytotoxicity (urothelial cells) |
Cellular |
| 795 |
Increase, Regenerative cell proliferation (urothelial cells) |
Increase, Regenerative cell proliferation (urothelial cells) |
Cellular |
| 796 |
Increase, Hyperplasia (urothelial) |
Increase, Hyperplasia (urothelial) |
Cellular |
| 797 |
Increase, Adenomas/carcinomas (urothelial) |
Increase, Adenomas/carcinomas (urothelial) |
Tissue |
| 798 |
Inhibition, Prolyl hydroxylases |
Inhibition, Prolyl hydroxylases |
Cellular |
| 799 |
Increased, HIF-1 heterodimer |
Increased, HIF-1 heterodimer |
Cellular |
| 800 |
Decreased, Aromatase (Cyp19a1) mRNA |
Decreased, Aromatase (Cyp19a1) mRNA |
Cellular |
| 801 |
modulation, Unknown |
modulation, Unknown |
Molecular |
| 802 |
Increased, HIF-1 alpha transcription |
Increased, HIF-1 alpha transcription |
Cellular |
| 804 |
Inhibition, HMG-CoA reductase |
Inhibition, HMG-CoA reductase |
Cellular |
| 805 |
Decreased, mevalonate |
Decreased, mevalonate |
Cellular |
| 807 |
Decreased, cholesterol |
Decreased, cholesterol |
Tissue |
| 808 |
Decreased, Testosterone |
Decreased, Testosterone |
Individual |
| 809 |
malformed, Male reproductive tract |
malformed, Male reproductive tract |
Individual |
| 813 |
Increased, Serum creatinine |
Increased, Serum creatinine |
Organ |
| 814 |
Occurrence, Kidney toxicity |
Occurrence, Kidney toxicity |
Organ |
| 818 |
Occurrence, Cytoplasmic vacuolization (Renal tubule) |
Occurrence, Cytoplasmic vacuolization (Renal tubule) |
Organ |
| 819 |
Decreased, Glomerular filtration |
Decreased, Glomerular filtration |
Tissue |
| 820 |
Decreased, Renal plasma flow |
Decreased, Renal plasma flow |
Tissue |
| 821 |
Decreased, Sodium reabsorption |
Decreased, Sodium reabsorption |
Organ |
| 823 |
Occurrence, Cystic dilatation (renal tubule) |
Occurrence, Cystic dilatation (renal tubule) |
Organ |
| 824 |
Occurrence, Cytoplasmic vacuolization (podocyte) |
Occurrence, Cytoplasmic vacuolization (podocyte) |
Organ |
| 825 |
Decreased, Renal ability to dilute urine |
Decreased, Renal ability to dilute urine |
Organ |
| 826 |
Activation, Keratinocytes |
Activation, Keratinocytes |
Cellular |
| 827 |
sensitisation, skin |
sensitisation, skin |
Organ |
| 828 |
Inhibition, Phospholipase A |
Inhibition, Phospholipase A |
Molecular |
| 829 |
Damage, Lipid bilayer |
Damage, Lipid bilayer |
Cellular |
| 831 |
Disturbance, Lysosomal function |
Disturbance, Lysosomal function |
Cellular |
| 832 |
Injury, Mitochondria |
Injury, Mitochondria |
Cellular |
| 833 |
Occurrence, Cytoplasmic vacuolization (hepatocyte) |
Occurrence, Cytoplasmic vacuolization (hepatocyte) |
Cellular |
| 835 |
Occurrence, Ballooning degeneration (hepatocyte) |
Occurrence, Ballooning degeneration (hepatocyte) |
Cellular |
| 836 |
Occurrence, Cytoplasmic vacuolization (Bile duct cell) |
Occurrence, Cytoplasmic vacuolization (Bile duct cell) |
Cellular |
| 837 |
Occurrence, Cytoplasmic vacuolization (kupffer cell) |
Occurrence, Cytoplasmic vacuolization (kupffer cell) |
Cellular |
| 838 |
Induction, Microvesicular fat |
Induction, Microvesicular fat |
Tissue |
| 839 |
Formation, Mallory body |
Formation, Mallory body |
Cellular |
| 840 |
Formation, Liver fibrosis |
Formation, Liver fibrosis |
Tissue |
| 844 |
Oxidation, Uroporphyrinogen |
Oxidation, Uroporphyrinogen |
Cellular |
| 845 |
Inhibition, UROD |
Inhibition, UROD |
Molecular |
| 846 |
Accumulation, Highly carboxylated porphyrins |
Accumulation, Highly carboxylated porphyrins |
Organ |
| 848 |
Decreased, Binding of NE to NE receptors on GnRH neurons |
Decreased, Binding of NE to NE receptors on GnRH neurons |
Cellular |
| 849 |
Inhibition, Antgonism of NE receptor |
Inhibition, Antgonism of NE receptor |
Molecular |
| 850 |
Induction, CYP1A2/CYP1A5 |
Induction, CYP1A2/CYP1A5 |
Molecular |
| 851 |
Decrease of GABAergic interneurons |
GABAergic interneurons, Decreased |
Cellular |
| 853 |
Changes/Inhibition, Cellular Homeostasis and Apoptosis |
Changes/Inhibition, Cellular Homeostasis and Apoptosis |
Cellular |
| 854 |
Alterations, Cellular proliferation / hyperplasia |
Alterations, Cellular proliferation / hyperplasia |
Tissue |
| 856 |
Formation, Hepatocellular and Bile duct tumors |
Formation, Hepatocellular and Bile duct tumors |
Organ |
| 857 |
Binding as antagonist, Antagonist binding to PPARalpha ligand binding domain |
Binding as antagonist, Antagonist binding to PPARalpha ligand binding domain |
Molecular |
| 858 |
Decreased, PPARalpha transactivation of gene expression |
Decreased, PPARalpha transactivation of gene expression |
Molecular |
| 859 |
Decreased, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids |
Decreased, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids |
Molecular |
| 860 |
Decreased, Mitochondrial Fatty Acid Beta Oxidation |
Decreased, Mitochondrial Fatty Acid Beta Oxidation |
Molecular |
| 861 |
Decreased, Ketogenesis (production of ketone bodies) |
Decreased, Ketogenesis (production of ketone bodies) |
Cellular |
| 862 |
Not Increased, Circulating Ketone Bodies |
Not Increased, Circulating Ketone Bodies |
Tissue |
| 863 |
Increased, Catabolism of Muscle Protein |
Increased, Catabolism of Muscle Protein |
Organ |
| 864 |
Decreased, Body Weight |
Decreased, Body Weight |
Individual |
| 867 |
Decrease, Intracellular pH |
Decrease, Intracellular pH |
Cellular |
| 868 |
Increase, Tissue Degeneration, Necrosis & Atrophy |
Increase, Tissue Degeneration, Necrosis & Atrophy |
Tissue |
| 869 |
Increase, Respiratory or Squamous Metaplasia |
Increase, Respiratory or Squamous Metaplasia |
Tissue |
| 870 |
Increase, Cell Proliferation |
Increase, Cell Proliferation |
Cellular |
| 872 |
Increase, Site of Contact Nasal Tumors |
Increase, Site of Contact Nasal Tumors |
Organ |
| 875 |
Binding of agonist, Ionotropic glutamate receptors |
Binding of agonist, Ionotropic glutamate receptors |
Molecular |
| 876 |
Increase, Mutations in Critical Genes |
Increase, Mutations in Critical Genes |
Molecular |
| 877 |
Inhibition, organic anion transporter 1 (OAT1) |
Inhibition, organic anion transporter 1 (OAT1) |
Molecular |
| 878 |
Inhibition, SREBP1c |
Inhibition, SREBP1c |
Molecular |
| 879 |
Activation, MTTP |
Activation, MTTP |
Cellular |
| 880 |
Increased, ApoB100 |
Increased, ApoB100 |
Tissue |
| 881 |
Increased, Triglyceride |
Increased, Triglyceride |
Cellular |
| 885 |
Increase, Cancer |
Increase, Cancer |
Tissue |
| 887 |
Inhibition, NADH-ubiquinone oxidoreductase (complex I) |
Inhibition, NADH-ubiquinone oxidoreductase (complex I) |
Cellular |
| 888 |
Binding of inhibitor, NADH-ubiquinone oxidoreductase (complex I) |
Binding of inhibitor, NADH-ubiquinone oxidoreductase (complex I) |
Molecular |
| 889 |
Impaired, Proteostasis |
Impaired, Proteostasis |
Cellular |
| 890 |
Degeneration of dopaminergic neurons of the nigrostriatal pathway |
Degeneration of dopaminergic neurons of the nigrostriatal pathway |
Organ |
| 896 |
Parkinsonian motor deficits |
Parkinsonian motor deficits |
Individual |
| 898 |
Disruption, Lysosome |
Disruption, Lysosome |
Cellular |
| 901 |
Infiltration, Inflammatory cells |
Infiltration, Inflammatory cells |
Tissue |
| 902 |
Inflammation, Liver |
Inflammation, Liver |
Organ |
| 907 |
Infiltration, Inflammatory cytokines |
Infiltration, Inflammatory cytokines |
|
| 913 |
Activation, Epidermal Growth Factor Receptor |
Activation, Epidermal Growth Factor Receptor |
|
| 914 |
Decrease, Apoptosis of ciliated epithelial cells |
Decreased ciliated cell apoptosis |
Cellular |
| 919 |
Occurrence, Transdifferentiation of ciliated epithelial cells |
Occurrence, Transdifferentiation of ciliated epithelial cells |
Cellular |
| 920 |
Occurrence, Metaplasia of goblet cells |
Goblet cell metaplasia |
Tissue |
| 921 |
Occurrence, Hyperplasia of goblet cells |
Goblet cell hyperplasia |
Tissue |
| 923 |
Increase, Proliferation of goblet cells |
Increased goblet cell proliferation |
Cellular |
| 924 |
Activation, Sp1 |
Activation, Sp1 |
Molecular |
| 926 |
Oxidation, Glutathione (To be considered with MIE) |
Oxidation, Glutathione |
Molecular |
| 927 |
KE1 : S-Glutathionylation, eNOS |
S-Glutathionylation, eNOS |
Molecular |
| 932 |
KE4 : Uncoupling, eNOS |
Uncoupling, eNOS |
Cellular |
| 933 |
KE6 : Depletion, Nitric Oxide |
Depletion, Nitric Oxide |
Cellular |
| 934 |
KE3 : Decrease, Tetrahydrobiopterin |
Decrease, Tetrahydrobiopterin |
Cellular |
| 935 |
KE2 : Decrease, GTPCH-1 |
Decrease, GTPCH-1 |
Cellular |
| 937 |
KE7 : Impaired, Vasodilation |
Impaired, Vasodilation |
Organ |
| 941 |
Activation, EGFR |
Activation, EGFR |
Molecular |
| 943 |
Hypersecretion, Mucus |
Hypersecretion, Mucus |
Organ |
| 944 |
dimerization, AHR/ARNT |
dimerization, AHR/ARNT |
Molecular |
| 945 |
reduced dimerization, ARNT/HIF1-alpha |
reduced dimerization, ARNT/HIF1-alpha |
Molecular |
| 947 |
Increase, Early Life Stage Mortality |
Increase, Early Life Stage Mortality |
Individual |
| 948 |
reduced production, VEGF |
reduced production, VEGF |
Cellular |
| 951 |
KE8 : Increase, Vascular Resistance |
Increase, Vascular Resistance |
Organ |
| 952 |
Hypertension |
Hypertension |
Individual |
| 957 |
Binding, Transthyretin in serum |
Binding, Transthyretin in serum |
Molecular |
| 958 |
Displacement, Serum thyroxine (T4) from transthyretin |
Displacement, Serum thyroxine (T4) from transthyretin |
Molecular |
| 959 |
Increased, Free serum thyroxine (T4) |
Increased, Free serum thyroxine (T4) |
Tissue |
| 960 |
Increased, Uptake of thyroxine into tissue |
Increased, Uptake of thyroxine into tissue |
Cellular |
| 961 |
Increased, Clearance of thyroxine from serum |
Increased, Clearance of thyroxine from serum |
Tissue |
| 962 |
Increase, Mucin production |
Increase, Mucin production |
Cellular |
| 964 |
Inhibition of Aromatase Enzyme, Chemical exposure during critical window of estrous cycle between diestrus 2 and proestrus inhibits aromatase conversion of testosterone to estradiol |
Inhibition of Aromatase Enzyme, Chemical exposure during critical window of estrous cycle b |
Molecular |
| 965 |
reduction in ovarian granulosa cells synthesis of estradiol, Reduced steroidogenic production of estradiol in granulosa cells |
reduction in ovarian granulosa cells synthesis of estradiol, Reduced steroidogenic producti |
Cellular |
| 966 |
Reduced Estradiol in Circulation, Reduced steroidogenic production of estradiol in granulosa cells leading to decreased estradiol in circulation |
Reduced Estradiol in Circulation, Reduced steroidogenic production of estradiol in granulos |
Tissue |
| 967 |
Decreased positive estrogenic feedback on hypothalamus, Reduced estradiol in circulation decreases estrogen concentration at hypothalamus |
Decreased positive estrogenic feedback on hypothalamus, Reduced estradiol in circulation de |
Organ |
| 968 |
Decreased Kisspeptin release from neurons in AVPV, Decreased hypothalamic estrogen reduces kisspeptinergic neuron response |
Decreased Kisspeptin release from neurons in AVPV, Decreased hypothalamic estrogen reduces |
Cellular |
| 969 |
Decreased GnRH Release, Decreased Kisspeptin stimulation of GnRH neurons |
Decreased GnRH Release, Decreased Kisspeptin stimulation of GnRH neurons |
Cellular |
| 970 |
Decreased LH release from Anterior Pituitary, Decreased GnRH stimulation of Anterior Pituitary Gonadotrophs |
Decreased LH release from Anterior Pituitary, Decreased GnRH stimulation of Anterior Pituit |
Cellular |
| 971 |
Ovulation of oocytes Reduced, Delayed, or Blocked, Decrease or delay in LH surge required for ovulation |
Reduced Ovulation of oocytes |
Individual |
| 972 |
Decreased fertility, Reduced number of oocytes ovulated |
Decreased fertility, Reduced number of oocytes ovulated |
Individual |
| 973 |
KE5 : Decrease, AKT/eNOS activity |
Decrease, AKT/eNOS activity |
Cellular |
| 974 |
The binding of FK506 with FKBP12, |
The binding of FK506 with FKBP12, |
|
| 975 |
The binding of FK506 with FKBP12, The binding of FK506 with FKBP12 |
The binding of FK506 with FKBP12, The binding of FK506 with FKBP12 |
|
| 976 |
Formation, The binding of FK506 with FKBP12 |
Formation, The binding of FK506 with FKBP12 |
Molecular |
| 977 |
Binding, Binding of calcineurin with FK506-FKBP complexes |
Binding, Binding of calcineurin with FK506-FKBP complexes |
|
| 978 |
Activation, Suppression of NFAT activation and hindrance of nuclear localization |
Activation, Suppression of NFAT activation and hindrance of nuclear localization |
Molecular |
| 979 |
Interference, nuclear localization of NFAT |
Interference, nuclear localization of NFAT |
Molecular |
| 980 |
Inhibition, Calcineurin Activity |
Inhibition, Calcineurin Activity |
Molecular |
| 981 |
Reduction, NFAT/AP-1 complex formation |
Reduction, NFAT/AP-1 complex formation |
Cellular |
| 982 |
Suppression, Suppression in mixed lymphocyte reaction (MLR) |
Suppression, Suppression in mixed lymphocyte reaction (MLR) |
Cellular |
| 983 |
Suppression, Suppression of T-cell dependent antibody response (TDAR) |
Suppression, Suppression of T-cell dependent antibody response (TDAR) |
Cellular |
| 984 |
Impairment, T-cell dependent antibody response |
Impairment, T-cell dependent antibody response |
Individual |
| 985 |
Relief, Relief of atopic dermatitis |
Relief, Relief of atopic dermatitis |
Individual |
| 986 |
Impairment of TDAR |
Impairment of TDAR |
Individual |
| 987 |
Metaplasia of goblet cells |
Metaplasia of goblet cells |
Molecular |
| 988 |
Decrease, Circulating ecdysis triggering hormone |
Decrease, Circulating ETH |
Tissue |
| 989 |
Decreased, synthesis and secretion of molting fluid proteases |
Decreased, synthesis and secretion of molting fluid proteases |
|
| 990 |
Increase, Incomplete ecdysis |
Increase, Incomplete ecdysis |
Individual |
| 992 |
Decreased, Population 2 |
Decreased, Population 2 |
|
| 993 |
Decrease, Abdominal muscle contraction |
Decrease, Abdominal muscle contraction |
Tissue |
| 994 |
Decreased, Synthesis of molting fluid proteases |
Decreased, Synthesis of molting fluid proteases |
Tissue |
| 996 |
Decrease, Digestion of old cuticle |
Decrease, Digestion of old cuticle |
Organ |
| 997 |
Decreased, Population size |
Decreased, Population size |
Population |
| 998 |
Binding of antagonist, PPAR alpha |
Binding of antagonist, PPAR alpha |
Molecular |
| 999 |
stabilization, co-repressor |
stabilization, co-repressor |
|
| 1000 |
stabilization, PPAR alpha co-repressor |
stabilization, PPAR alpha co-repressor |
Molecular |
| 1001 |
Increased, Developmental Defects |
Increased, Developmental Defects |
Molecular |
| 1002 |
Inhibition, Deiodinase 2 |
Inhibition, Deiodinase 2 |
Molecular |
| 1003 |
Decreased, Triiodothyronine (T3) |
Decreased, Triiodothyronine (T3) |
Tissue |
| 1004 |
Reduced, Posterior swim bladder inflation |
Reduced, Posterior swim bladder inflation |
Organ |
| 1005 |
Reduced, Swimming performance |
Reduced, Swimming performance |
Individual |
| 1007 |
Reduced, Anterior swim bladder inflation |
Reduced, Anterior swim bladder inflation |
Organ |
| 1008 |
Reduced, Hearing |
Reduced, Hearing |
Organ |
| 1009 |
Inhibition, Deiodinase 1 |
Inhibition, Deiodinase 1 |
Molecular |
| 1011 |
Increased, Chloride influx |
Increased, Chloride influx |
|
| 1012 |
Increased, Inhibitory postsynaptic potential |
Increased, Inhibitory postsynaptic potential |
Cellular |
| 1013 |
Inhibition, Motor neuron activity |
Inhibition, Motor neuron activity |
|
| 1014 |
Induction, Somatic muscle paralysis |
Induction, Somatic muscle paralysis |
Tissue |
| 1015 |
Increased, Neuronal synaptic inhibition |
Increased, Neuronal synaptic inhibition |
Cellular |
| 1016 |
Inhibition, Feeding |
Inhibition, Feeding |
Individual |
| 1017 |
Reduced, Feeding 2 |
Reduced, Feeding 2 |
|
| 1018 |
Activation, Glutamate-gated chloride channels |
Activation, Glutamate-gated chloride channels |
Molecular |
| 1019 |
Induction, pharyngeal muscle paralysis |
Induction, pharyngeal muscle paralysis |
Tissue |
| 1020 |
Increased, induction of UDPGT's in liver |
Increased, induction of UDPGT's in liver |
Cellular |
| 1021 |
Increased, T4/T3 catabolism |
Increased, T4/T3 catabolism |
Cellular |
| 1022 |
Decreased, serum T4/T3 |
Decreased, serum T4/T3 |
Tissue |
| 1023 |
Increased, Thyroid-stimulating hormone (TSH) |
Increased, Thyroid-stimulating hormone (TSH) |
Tissue |
| 1024 |
Increased, Hypertrophy and proliferation (follicular cell) |
Increased, Hypertrophy and proliferation (follicular cell) |
Cellular |
| 1025 |
Increased, Hyperplasia (follicular cells) |
Increased, Hyperplasia (follicular cells) |
Tissue |
| 1026 |
Increased Apoptosis, Adenomas/carcinomas (follicular cell) |
Increased Apoptosis, Adenomas/carcinomas (follicular cell) |
Tissue |
| 1027 |
, Learning and memory, impairment |
, Learning and memory, impairment |
|
| 1028 |
Activation of specific nuclear receptors, PPAR-gamma activation |
Activation of specific nuclear receptors, PPAR-gamma activation |
Molecular |
| 1029 |
Increased, adipogenesis |
Increased, adipogenesis |
Cellular |
| 1030 |
Increased, |
Increased, |
|
| 1031 |
Increased, release of growth factors |
Increased, release of growth factors |
|
| 1032 |
Increased, secretion of local growth factors |
Increased, secretion of local growth factors |
Cellular |
| 1033 |
Increased, proliferation of mesenchymal cells |
Increased, proliferation of mesenchymal cells |
Cellular |
| 1034 |
Increased, IGF-1 (mouse) |
Increased, IGF-1 (mouse) |
Cellular |
| 1035 |
Increased, Firbrosarcoma |
Increased, Firbrosarcoma |
Tissue |
| 1036 |
Increased, liposarcoma |
Increased, liposarcoma |
Tissue |
| 1037 |
Increased, hemagiosarcoma |
Increased, hemagiosarcoma |
Tissue |
| 1038 |
Activation, beta-2 adrenergic receptor |
Activation, beta-2 adrenergic receptor |
Molecular |
| 1039 |
Increased activity, beta-2 adrenergic receptor |
Increased activity, beta-2 adrenergic receptor |
Molecular |
| 1040 |
relaxation, smooth muscle |
relaxation, smooth muscle |
Tissue |
| 1041 |
Proliferation, smooth muscle |
Proliferation, smooth muscle |
|
| 1042 |
Proliferation/Clonal Expansion, smooth muscle |
Proliferation/Clonal Expansion, smooth muscle |
Cellular |
| 1043 |
Hypertrophy/hyperplasia, smooth muscle |
Hypertrophy/hyperplasia, smooth muscle |
Cellular |
| 1044 |
Promotion, mesovarian leiomyomas |
Promotion, mesovarian leiomyomas |
Tissue |
| 1045 |
Decreased, Ovarian E2 |
Decreased, Ovarian E2 |
Tissue |
| 1046 |
Suppression, Estrogen receptor (ER) activity |
Suppression, Estrogen receptor (ER) activity |
Molecular |
| 1047 |
Increased, secretion of GnRH from hypothalamus |
Increased, secretion of GnRH from hypothalamus |
Cellular |
| 1048 |
Increased, secretion of leutenizing hormone |
Increased, secretion of leutenizing hormone |
|
| 1049 |
Increased, secrection of FSH from anterior pituitary |
Increased, secrection of FSH from anterior pituitary |
Cellular |
| 1050 |
Increased, secretion of LH from anterior pituitary |
Increased, secretion of LH from anterior pituitary |
Cellular |
| 1051 |
Hyperplasia, ovarian stromal cells |
Hyperplasia, ovarian stromal cells |
Cellular |
| 1052 |
Hyperplasia, ovarian epithelium |
Hyperplasia, ovarian epithelium |
Tissue |
| 1053 |
Promotion, ovarian adenomas |
Promotion, ovarian adenomas |
Tissue |
| 1054 |
Promotion, ovarian granular cell tumors |
Promotion, ovarian granular cell tumors |
Cellular |
| 1055 |
Decreased, Reduced estradiol in circulation decreases estrogen concentration at hypothalamus |
Decreased, Reduced estradiol in circulation decreases estrogen concentration at hypothalamu |
|
| 1056 |
Decrease, E2 blood concentrations at hypothalamus |
Decrease, E2 blood concentrations at hypothalamus |
Tissue |
| 1057 |
Increased, PPAR-alpha activation |
Increased, PPAR-alpha activation |
Molecular |
| 1058 |
Decreased, bile flow |
Decreased, bile flow |
Organ |
| 1059 |
Increased, cholestasis |
Increased, cholestasis |
Organ |
| 1060 |
Alteration, lipid metabolism |
Alteration, lipid metabolism |
Cellular |
| 1061 |
prolonged, elevation of serun CCK |
prolonged, elevation of serun CCK |
Tissue |
| 1062 |
Increased, Cellular proliferation / hyperplasia of acinar cells |
Increased, Cellular proliferation / hyperplasia of acinar cells |
Cellular |
| 1063 |
Increased, Pancreatic acinar tumors |
Increased, Pancreatic acinar tumors |
Organ |
| 1064 |
prepubertal increase, Estrogen receptor (ER) activity |
prepubertal increase, Estrogen receptor (ER) activity |
Molecular |
| 1065 |
Activation, estrogen receptor alpha |
Activation, estrogen receptor alpha |
Molecular |
| 1066 |
Promotion, SIX-1 postive basal-type progenitor cells |
Promotion, SIX-1 postive basal-type progenitor cells |
Cellular |
| 1067 |
Proliferation/Clonal Expansion, aberrant basal cells |
Proliferation/Clonal Expansion, aberrant basal cells |
Cellular |
| 1068 |
squamous metaplasia, aberrant basal cells |
squamous metaplasia, aberrant basal cells |
Tissue |
| 1069 |
Increased, Hyperplasia (glandular epithelial cells of endometrium) |
Increased, Hyperplasia (glandular epithelial cells of endometrium) |
Cellular |
| 1070 |
Increased, adenosquamous carcinomas of endometrium |
Increased, adenosquamous carcinomas of endometrium |
Tissue |
| 1071 |
Decreased, GnRH pulsatility/release in hypothalamus |
Decreased, GnRH pulsatility/release in hypothalamus |
Cellular |
| 1072 |
Decreased, LH Surge from anterior pituitary |
Decreased, LH Surge from anterior pituitary |
Cellular |
| 1073 |
anovulation, |
anovulation, |
|
| 1074 |
interruption, Ovulation |
interruption, Ovulation |
Individual |
| 1075 |
prolonged, estrus |
prolonged, estrus |
Individual |
| 1076 |
Increased, circulating estrogen levels |
Increased, circulating estrogen levels |
Organ |
| 1077 |
Increased, prolactin exposure |
Increased, prolactin exposure |
Tissue |
| 1078 |
Hyperplasia, Mammary gland |
Hyperplasia, Mammary gland |
Tissue |
| 1079 |
Increased, Adenomas/carcinomas (mammary) |
Increased, Adenomas/carcinomas (mammary) |
Tissue |
| 1080 |
Increased, latency period |
Increased, latency period |
Individual |
| 1081 |
Increased, lactotroph hyperplasia and hypertrophy |
Increased, lactotroph hyperplasia and hypertrophy |
Cellular |
| 1082 |
Increased, adenomas (pituitary) |
Increased, adenomas (pituitary) |
Tissue |
| 1083 |
Decreased, Dopaminergic activity |
Decreased, Dopaminergic activity |
Cellular |
| 1084 |
Increased, prolactin secretion |
Increased, prolactin secretion |
Tissue |
| 1085 |
Increased, hyperplasia (mammary gland) |
Increased, hyperplasia (mammary gland) |
Tissue |
| 1086 |
persistent, cytotoxicity (pleura or peritoneum) |
persistent, cytotoxicity (pleura or peritoneum) |
Cellular |
| 1087 |
Increased, inflammation |
Increased, inflammation |
Cellular |
| 1088 |
Increased, Oxidative Stress |
Increased, Oxidative Stress |
Molecular |
| 1089 |
Increased, Cell Proliferation (mesothelium) |
Increased, Cell Proliferation (mesothelium) |
Cellular |
| 1090 |
Increased, mesotheliomas |
Increased, mesotheliomas |
Tissue |
| 1091 |
Physical and/or chemical interaction with cellular components, |
Physical and/or chemical interaction with cellular components, |
|
| 1092 |
Pulmonary Fibrosis, |
Pulmonary Fibrosis, |
|
| 1093 |
Decreased, Thyroxine (T4) in tissues |
Decreased, Thyroxine (T4) in tissues |
Tissue |
| 1094 |
, hyperuricemia |
, hyperuricemia |
|
| 1095 |
hyperuricemia, |
hyperuricemia, |
|
| 1096 |
Increased, blood uric acid concentration |
Increased, blood uric acid concentration |
Tissue |
| 1097 |
Occurrence, renal proximal tubular necrosis |
Occurrence, renal proximal tubular necrosis |
Tissue |
| 1098 |
Increased, blood potassium concentration |
Increased, blood potassium concentration |
Tissue |
| 1100 |
Occurrence, cardiac arrthymia |
Occurrence, cardiac arrthymia |
|
| 1101 |
Altered, Amphibian metamorphosis |
Altered, Amphibian metamorphosis |
Organ |
| 1102 |
Occurrence, tophi (urate) deposition |
Occurrence, tophi (urate) deposition |
Tissue |
| 1103 |
Inhibition, Cyclooxygenase 1 activity |
Inhibition, Cyclooxygenase 1 activity |
Molecular |
| 1104 |
Decreased, Prostaglandin F2alpha concentration, plasma |
Decreased, Prostaglandin F2alpha concentration, plasma |
Tissue |
| 1105 |
Occurrence, renal ischemia |
Occurrence, renal ischemia |
Tissue |
| 1106 |
Occurrence, cardiac arrhythmia |
Occurrence, cardiac arrhythmia |
Organ |
| 1107 |
Weakened, Colony |
Weakened, Colony |
Population |
| 1108 |
Abnormal, Role change within caste |
Abnormal, Role change within caste |
Population |
| 1109 |
Increased, Deformed Wing Virus levels |
Increased, Deformed Wing Virus levels |
Individual |
| 1110 |
Increased, Energetic demands and therefore metabolic stress |
Increased, Energetic demands and therefore metabolic stress |
Individual |
| 1111 |
weaj, |
weaj, |
|
| 1112 |
Occurrence, Oxidative Stress |
Occurrence, Oxidative Stress |
|
| 1113 |
Unknown, |
Unknown, |
|
| 1114 |
Unknown, MIE |
Unknown, MIE |
Molecular |
| 1115 |
Increased, Reactive oxygen species |
Increased, Reactive oxygen species |
Cellular |
| 1116 |
Decreased, Triiodothyronine (T3) in tissues |
Decreased, Triiodothyronine (T3) in tissues |
Tissue |
| 1117 |
Irreversible inhibition of VKOR by binding at tyrosine 139, |
Irreversible inhibition of VKOR by binding at tyrosine 139, |
|
| 1118 |
Irreversible inhibition of VKOR by binding of AR at tyrosine 139, Failure to cycle vitamin K epoxide to vitamin K to form vitamin K hydroquinone |
Irreversible inhibition of VKOR by binding of AR at tyrosine 139, Failure to cycle vitamin |
|
| 1119 |
Failure in gamma-glutamyl carboxylation of glutamine residues on clotting factors II, VII, IX and X, Under carboxylation of clotting factors (e.g., des-gamma-carboxy prothrombin) |
Failure in gamma-glutamyl carboxylation of glutamine residues on clotting factors II, VII, |
|
| 1120 |
Under carboxylated clotting factors will not assemble on cell surfaces , Failure to form clot |
Under carboxylated clotting factors will not assemble on cell surfaces , Failure to form cl |
|
| 1121 |
Hemorrhage , organ dysfunction, hypovolemic shock |
Hemorrhage , organ dysfunction, hypovolemic shock |
|
| 1122 |
Under carboxylated clotting factors will not assemble on cell surfaces to form clot, Failure of secondary hemostasis |
Under carboxylated clotting factors will not assemble on cell surfaces to form clot, Failur |
Tissue |
| 1123 |
Hemorrhage, organ dysfunction, hypovolemic shock, Impaired oxygen delivery to tissue |
Hemorrhage, organ dysfunction, hypovolemic shock, Impaired oxygen delivery to tissue |
|
| 1124 |
Hemorrhage , Impaired oxygen delivery and nutrient delivery to tissue, impaired carbon dioxide and waste product removal |
Hemorrhage , Impaired oxygen delivery and nutrient delivery to tissue, impaired carbon diox |
|
| 1125 |
Impaired oxygen and nutrient delivery to tissue, impaired removal of carbon dioxide and other waste products, Hemorrhage, organ dysfunction and hypovolemic shock |
Impaired oxygen and nutrient delivery to tissue, impaired removal of carbon dioxide and oth |
|
| 1126 |
Unresolved blood loss, Failure in vascular repair mechanisms |
Unresolved blood loss, Failure in vascular repair mechanisms |
|
| 1127 |
Anemia, Impaired oxygen and nutrient delivery to tissue, impaired carbon dioxide and waste product removal |
Anemia, Impaired oxygen and nutrient delivery to tissue, impaired carbon dioxide and waste |
|
| 1128 |
Unresolved hemorrhage, Failure in vascular repair mechanisms |
Unresolved hemorrhage, Failure in vascular repair mechanisms |
|
| 1129 |
Unresolved blood loss (hemorrhage), Failure in vascular repair mechanisms |
Unresolved blood loss (hemorrhage), Failure in vascular repair mechanisms |
|
| 1130 |
Failure in vascular repair mechanisms, Unresolved blood loss (hemorrhage) |
Failure in vascular repair mechanisms, Unresolved blood loss (hemorrhage) |
Organ |
| 1131 |
Failure in gamma-glutamyl carboxylation of clotting factors II, VII, IX and X, Under carboxylation of clotting factors (e.g., des-gamma-carboxy prothrombin) |
Failure in gamma-glutamyl carboxylation of clotting factors II, VII, IX and X, Under carbo |
Molecular |
| 1132 |
Blood loss and development of anemia, Impaired oxygen delivery and nutrient delivery to tissue, impaired carbon dioxide and waste product removal |
Blood loss and development of anemia, Impaired oxygen delivery and nutrient delivery to tis |
Cellular |
| 1133 |
Hemostasis, Depletion from blood of fully functional carboxylated clotting factors |
Hemostasis, Depletion from blood of fully functional carboxylated clotting factors |
Tissue |
| 1134 |
Irreversible inhibition of hepatic VKOR by binding of AR at tyrosine 139, Failure to cycle vitamin K epoxide to vitamin K to form vitamin K hydroquinone |
Irreversible inhibition of hepatic VKOR by binding of AR at tyrosine 139, Failure to cycle |
Molecular |
| 1135 |
Reduced fitness or even mortality, Acidosis, hypovolemic shock and organ dysfunction |
Reduced fitness or even mortality, Acidosis, hypovolemic shock and organ dysfunction |
Tissue |
| 1136 |
Impaired recruitment , Population trajectory |
Impaired recruitment , Population trajectory |
Population |
| 1137 |
Under carboxylation of osteocalcin, Failure to cycle vitamin K epoxide to vitamin K to form vitamin K hydroquinone |
Under carboxylation of osteocalcin, Failure to cycle vitamin K epoxide to vitamin K to form |
|
| 1138 |
Uncoupling of oxidative phosphorylation, Reduced ability to generate ATP |
Uncoupling of oxidative phosphorylation, Reduced ability to generate ATP |
Molecular |
| 1139 |
Increased, water retention in foot |
Increased, water retention in foot |
Organ |
| 1140 |
Delayed, Sexual maturity |
Delayed, Sexual maturity |
Individual |
| 1141 |
Decreased, Reproductive Success |
Decreased, Reproductive Success |
Individual |
| 1142 |
Increased, valve movement |
Increased, valve movement |
Tissue |
| 1143 |
Depletion, energy reserves |
Depletion, energy reserves |
Individual |
| 1144 |
premature, spawning 1 1 |
premature, spawning 1 |
|
| 1145 |
Decreased, gametogenesis |
Decreased, gametogenesis |
|
| 1146 |
premature, Spawning |
premature, Spawning |
Individual |
| 1147 |
increased or inappropriate, mantel display |
increased or inappropriate, mantel display |
Individual |
| 1148 |
Anticoagulant rodenticide interferes with gamma-carboxyglutamate formation, Inhibition of protein synthesis in bone |
Anticoagulant rodenticide interferes with gamma-carboxyglutamate formation, Inhibition of p |
|
| 1149 |
Calcium cannot bind to the hydroxyapatite matrix of bone, Osteocalcin and other bone proteins (periostin, MGP and periostin like factor) not formed |
Calcium cannot bind to the hydroxyapatite matrix of bone, Osteocalcin and other bone protei |
|
| 1150 |
Uncarboxylated osteocalcin not incorporated into bone matrix, decreasing bone strength, Impaired function of osteocalcin and MGP |
Uncarboxylated osteocalcin not incorporated into bone matrix, decreasing bone strength, Imp |
|
| 1151 |
Osteoporosis and vascular calcification, Bone deterioration |
Osteoporosis and vascular calcification, Bone deterioration |
Individual |
| 1152 |
Inhibition, Iodotyrosine deiodinase (IYD) |
Inhibition, Iodotyrosine deiodinase (IYD) |
Molecular |
| 1153 |
Inhibition, Deiodinase 3 |
Inhibition, Deiodinase 3 |
Molecular |
| 1154 |
Increased, Triiodothyronine (T3) in tissues |
Increased, Triiodothyronine (T3) in tissues |
Tissue |
| 1155 |
Inhibition, Pendrin |
Inhibition, Pendrin |
Molecular |
| 1156 |
Inhibition, Dual oxidase |
Inhibition, Dual oxidase |
Molecular |
| 1157 |
Activation, Hepatic nuclear receptor(s) |
Activation, Hepatic nuclear receptor(s) |
Molecular |
| 1158 |
Increased, Hepatic thyroid hormone uptake/transport |
Increased, Hepatic thyroid hormone uptake/transport |
Tissue |
| 1159 |
Increased, reuptake of 5-HT (5-hydroxytryptamine transporter; sodium-dependent serotonin transporter |
Increased, reuptake of 5-HT (5-hydroxytryptamine transporter; sodium-dependent serotonin tr |
|
| 1160 |
Increased, mantel display |
Increased, mantel display |
Individual |
| 1161 |
Increased, oocyte maturation |
Increased, oocyte maturation |
Organ |
| 1162 |
Increased, cilia movement |
Increased, cilia movement |
Cellular |
| 1163 |
Increased, Reproductive Success |
Increased, Reproductive Success |
Individual |
| 1164 |
Increased, Population |
Increased, Population |
Population |
| 1165 |
Vitamin K inhibition, gamma-carboxylation of glutamate to Gla residues reduced in bone proteins e.g., periostin |
Vitamin K inhibition, gamma-carboxylation of glutamate to Gla residues reduced in bone prot |
|
| 1166 |
Increased, water pumping |
Increased, water pumping |
Tissue |
| 1167 |
induced, parturition |
induced, parturition |
Individual |
| 1168 |
Undercarboxylation of osteocalcin , Affects bone formation (osteoblast-osteoclast interaction, bone resorption) and glucose and lipid hoemostasis |
Undercarboxylation of osteocalcin , Affects bone formation (osteoblast-osteoclast interacti |
|
| 1169 |
Anticoagulant rodenticide interferes with carboxylation of Gla proteins in bone, Impairment of post-translational modification (carboxylation) of osteocalcin |
Anticoagulant rodenticide interferes with carboxylation of Gla proteins in bone, Impairment |
Molecular |
| 1170 |
Increase, Phenotypic enzyme activity |
Increase, Phenotypic enzyme activity |
Cellular |
| 1171 |
Increase, Clonal Expansion of Altered Hepatic Foci |
Increase, Clonal Expansion of Altered Hepatic Foci |
Cellular |
| 1172 |
Increase activation, Nuclear factor kappa B (NF-kB) |
Increase activation, Nuclear factor kappa B (NF-kB) |
Cellular |
| 1173 |
Increase, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids |
Increase, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids |
Molecular |
| 1174 |
Activation, NADPH Oxidase |
Activation, NADPH Oxidase |
Molecular |
| 1175 |
Increase, Genes involved in fatty acid oxidation |
Increase, Genes involved in fatty acid oxidation |
Cellular |
| 1176 |
Decreased, sodium conductance 2 |
Decreased, sodium conductance 2 |
Cellular |
| 1177 |
Decreased, Ionotropic GABA receptor chloride channel conductance |
Decreased, Ionotropic GABA receptor chloride channel conductance |
Cellular |
| 1178 |
Decreased, Chloride conductance |
Decreased, Chloride conductance |
|
| 1179 |
Decreased, GABA release |
Decreased, GABA release |
Cellular |
| 1180 |
Estrogen receptor activation, |
Estrogen receptor activation, |
|
| 1181 |
Activation, Estrogen receptor |
Activation, Estrogen receptor |
Molecular |
| 1182 |
Increase, Cell Proliferation (Epithelial Cells) |
Increase, Cell Proliferation (Epithelial Cells) |
Cellular |
| 1183 |
Decreased, Apoptosis (Epithelial Cells) |
Decreased, Apoptosis (Epithelial Cells) |
Cellular |
| 1184 |
Dysfunction, Mitochondrial Dynamics |
Dysfunction, Mitochondrial Dynamics |
|
| 1185 |
Mitochondrial Dysfunction, N/A |
Mitochondrial Dysfunction, N/A |
|
| 1186 |
N/A, Mitochondrial Dysfunction 2 |
N/A, Mitochondrial Dysfunction 2 |
|
| 1187 |
Increased, ER binding to DNA (classical pathway) |
Increased, ER binding to DNA (classical pathway) |
Molecular |
| 1188 |
Increased, ER binding to T.F. to DNA (non-classical pathway) |
Increased, ER binding to T.F. to DNA (non-classical pathway) |
Molecular |
| 1189 |
Increased, Proliferation (Endothelial cells) |
Increased, Proliferation (Endothelial cells) |
Cellular |
| 1190 |
Increased, Migration (Endothelial Cells) |
Increased, Migration (Endothelial Cells) |
Cellular |
| 1191 |
Increased, Non-genomic signaling |
Increased, Non-genomic signaling |
Cellular |
| 1192 |
Increased, Ductal Hyperplasia |
Increased, Ductal Hyperplasia |
Tissue |
| 1193 |
N/A, Breast Cancer |
N/A, Breast Cancer |
Individual |
| 1194 |
Increase, DNA damage |
Increase, DNA Damage |
Molecular |
| 1195 |
modulation, Extracellular Matrix Composition |
modulation, Extracellular Matrix Composition |
Cellular |
| 1196 |
Increased, Invasion |
Increased, Invasion |
Cellular |
| 1197 |
Activation, Fibroblasts |
Activation, Fibroblasts |
Cellular |
| 1198 |
Activation, Macrophages |
Activation, Macrophages |
Cellular |
| 1199 |
Binding of FK506 to FKBP12, |
Binding of FK506 to FKBP12, |
|
| 1200 |
Binding of FK506 to FKBP12, Formation |
Binding of FK506 to FKBP12, Formation |
|
| 1201 |
Binding, Immunophilins |
Binding, Immunophilins |
Molecular |
| 1202 |
Suppression, IL-2 and IL-4 production |
Suppression, IL-2 and IL-4 production |
Cellular |
| 1203 |
Suppression, Suppression of production of cytotoxic T-cells |
Suppression, Suppression of production of cytotoxic T-cells |
Tissue |
| 1204 |
Suppression, Suppression of T-cell dependent antibody production |
Suppression, Suppression of T-cell dependent antibody production |
Cellular |
| 1205 |
Activation, Juvenile hormone receptor |
Activation, Juvenile hormone receptor |
Molecular |
| 1206 |
Induction, Doublesex1 gene |
Induction, Doublesex1 gene |
Molecular |
| 1207 |
Induction, Male traits formation in embryos |
Induction, Male traits formation in embryos |
|
| 1208 |
Increased, Male offspring |
Increased, Male offspring |
Population |
| 1209 |
Induction, Male reproductive tract |
Induction, Male reproductive tract |
Organ |
| 1210 |
Alteration, Food-web structures |
Alteration, Food-web structures |
Population |
| 1211 |
Altered, food-web structures |
Altered, food-web structures |
Population |
| 1212 |
Reduced, Neuronal synaptic inhibition |
Reduced, Neuronal synaptic inhibition |
Cellular |
| 1213 |
Increased, Angiogenesis |
Increased, Angiogenesis |
Cellular |
| 1214 |
Altered gene expression specific to CAR activation, Hepatocytes |
Altered expression of hepatic CAR-dependent genes |
Cellular |
| 1215 |
TRPA1 activation, TRPA1 Receptor |
TRPA1 activation, TRPA1 Receptor |
Molecular |
| 1216 |
Influx of Ca2+, Excitation of trigeminal nerves |
Influx of Ca2+, Excitation of trigeminal nerves |
|
| 1217 |
Excitation of trigeminal nerves induces Sensory Airway Irritation, |
Sensory Airway Irritation |
Organ |
| 1218 |
Opening of calcium channel, Calcium influx |
Opening of calcium channel, Calcium influx |
Cellular |
| 1219 |
Release of Substance P (SP), Substance P increase in circulation |
Release of Substance P (SP), Substance P increase in circulation |
|
| 1220 |
Trigeminal nerve activation |
Excitation, Trigeminal nerve excitation |
Tissue |
| 1221 |
Cough, Dyspnea, Sneezing, Acute respiratory effect |
Cough, Dyspnea, Sneezing, Acute respiratory effect |
|
| 1222 |
SP (Substance P) release, Local increase of SP |
SP (Substance P) release, Local increase of SP |
Cellular |
| 1223 |
Trigeminal and/or vagal nerve excitation causes Airway Hyper-responsiveness,Cough, Dyspnea |
Increased Airway Hyper-responsiveness,Cough, Dyspnea |
Tissue |
| 1224 |
Non-neuronal production of TNF, Epithelial irritation |
Non-neuronal production of TNF, Epithelial irritation |
Individual |
| 1225 |
Immune system inflammation |
Leukocyte infiltration |
Tissue |
| 1226 |
Increased Respiratory irritability and Chronic Cough, |
Respiratory irritability |
Organ |
| 1227 |
TRPA1 activation, Chemical covalent binding to sulfhydyl group on TRPA1 receptor protein/NEK293 fibroblast cells |
TRPA1 activation, Chemical covalent binding to sulfhydyl group on TRPA1 receptor protein/NE |
|
| 1228 |
TRPA1 activation, Classic receptor binding / HEK 293 cells (fibroclast), cho cells (ovary), noncovalently linkked) |
TRPA1 activation, Classic receptor binding / HEK 293 cells (fibroclast), cho cells (ovary), |
|
| 1229 |
TRPA1 activation, Chemical covalent binding to sulfhydyl group on TRPA1 receptor protein/ HEK293 fibroblast cells |
TRPA1 activation, Chemical covalent binding to sulfhydyl group on TRPA1 receptor protein/ H |
|
| 1230 |
TRPV1 activation, TRPV1 |
TRPV1 activation, TRPV1 |
Molecular |
| 1231 |
Oxidization of biomolecules, Lipid bilayer and cellular proteins |
Oxidization of biomolecules, Lipid bilayer and cellular proteins |
|
| 1232 |
Production of nerve growth factor , |
Production of nerve growth factor , |
|
| 1233 |
Production, Nerve growth factor |
Production, Nerve growth factor |
|
| 1234 |
Production of nerve growth factor , Epithelial irritation |
Production of nerve growth factor , Epithelial irritation |
Tissue |
| 1235 |
Non-neuronal production of IL-8/CXCL1, Epithelial irritation |
Non-neuronal production of IL-8/CXCL1, Epithelial irritation |
Tissue |
| 1236 |
Generation of novel epitopes , Antigen presentation |
Generation of novel epitopes , Antigen presentation |
Cellular |
| 1237 |
Sensitization, Immune system |
Sensitization, Immune system |
Individual |
| 1238 |
Activation of oxidative stress pathway |
Oxidation |
Molecular |
| 1239 |
Altered, Gene Expression |
Altered, Gene Expression |
Molecular |
| 1240 |
Altered, Protein Production |
Altered, Protein Production |
Cellular |
| 1241 |
Increased, Motility |
Increased, Motility |
Cellular |
| 1242 |
Increased, Second Messenger Production |
Increased, Second Messenger Production |
Cellular |
| 1243 |
Altered, Ca2+-calmodulin activated signal transduction |
Altered, Ca2+-calmodulin activated signal transduction |
Cellular |
| 1244 |
Mucus hypersecretion, |
Mucus hypersecretion, |
|
| 1245 |
Mucus , Hypersecretion |
Mucus , Hypersecretion |
|
| 1246 |
Lung function, Decrease |
Lung function, Decrease |
|
| 1247 |
EGFR , PPAR-alpha activation |
EGFR , PPAR-alpha activation |
|
| 1248 |
EGFR , Activation |
EGFR , Activation |
|
| 1249 |
Oxidative Stress, |
Oxidative Stress, |
|
| 1250 |
Decrease, Lung function |
Decreased lung function |
Individual |
| 1251 |
Chronic, Mucus hypersecretion |
Chronic, Mucus hypersecretion |
Tissue |
| 1252 |
Binding to (interferes with) topoisomerase II enzyme |
Binding, topoisomerase II |
Molecular |
| 1253 |
MLL chromosomal translocation |
MLL translocation |
Cellular |
| 1254 |
Infant leukaemia |
IFL |
Individual |
| 1255 |
induced spawning |
induced spawning |
Individual |
| 1256 |
increased mantel display |
increased mantel display |
Organ |
| 1257 |
Induced parturition |
Induced parturition |
Individual |
| 1258 |
Decompartmentalization |
Decompartmentalization |
Cellular |
| 1259 |
narcosis |
narcosis |
Cellular |
| 1260 |
Direct mitochondrial inhibition |
Direct mitochondrial inhibition |
Molecular |
| 1261 |
Mitochondrial impairment |
Mitochondrial impairment |
Molecular |
| 1262 |
Apoptosis |
Apoptosis |
Cellular |
| 1263 |
Necrosis |
Necrosis |
Tissue |
| 1264 |
Increase, Nuclear receptor E75b gene expression |
Increase, E75b expression |
Molecular |
| 1265 |
Increase, Fushi tarazu factor-1 gene expression |
Increase, Ftz-f1 expression |
Molecular |
| 1266 |
Decrease, Circulating crustacean cardioactive peptide |
Decrease, Circulating CCAP |
Tissue |
| 1267 |
Decrease, Ecdysis motoneuron bursts |
Decrease, Ecdysis motoneuron bursts |
Tissue |
| 1268 |
Decrease, Excitatory postsynaptic potential |
Decrease, Excitatory postsynaptic potential |
Tissue |
| 1269 |
Increase, COX-2 expression |
Increase, COX-2 expression |
Molecular |
| 1270 |
Inactivation of PPARγ |
Inactivation of PPARγ |
Molecular |
| 1271 |
Activation of TGF-β signaling |
Activation of TGF-β signaling |
Cellular |
| 1272 |
Differentiation of Myofibroblast |
Differentiation of Myofibroblast |
Cellular |
| 1273 |
Expression of Collagen |
Expression of Collagen |
Cellular |
| 1274 |
Production of α-smooth muscle actin |
Production of α-smooth muscle actin |
Cellular |
| 1275 |
Collagen Deposition |
Collagen Deposition |
Tissue |
| 1276 |
Lung fibrosis |
Lung fibrosis |
Organ |
| 1277 |
Reproductive failure |
Reproductive failure |
Individual |
| 1278 |
ROS formation |
ROS formation |
Molecular |
| 1279 |
Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK |
Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK |
Cellular |
| 1280 |
Activation, HIF-1 |
Activation, HIF-1 |
Cellular |
| 1281 |
Increased, DNA Damage-Repair |
Increased, DNA Damage-Repair |
Cellular |
| 1282 |
Activation, JAK/STAT pathway |
Activation, JAK/STAT pathway |
Cellular |
| 1283 |
Activation, TGF-beta pathway |
Activation, TGF-beta pathway |
Cellular |
| 1284 |
Up Regulation, SREBF2 |
Up Regulation, SREBF2 |
Cellular |
| 1285 |
Up Regulation, Unsaturated fatty acid |
Up Regulation, Unsaturated fatty acid |
Cellular |
| 1286 |
Down Regulation, GSS and GSTs gene |
Down Regulation, GSS and GSTs gene |
Cellular |
| 1287 |
Glutathione synthesis |
Glutathione synthesis |
Cellular |
| 1288 |
Activation, 3-hydroxy-3-methylglutaryl-CoA reductase gene |
Activation, 3-hydroxy-3-methylglutaryl-CoA reductase gene |
Cellular |
| 1289 |
Perturbation of cholesterol |
Perturbation of cholesterol |
Cellular |
| 1290 |
Glutathione homeostasis |
Glutathione homeostasis |
Cellular |
| 1291 |
Hepatotoxicity |
Hepatotoxicity |
Cellular |
| 1292 |
Activation, JNK |
Activation, JNK |
Cellular |
| 1293 |
Activation, FOXO |
Activation, FOXO |
Cellular |
| 1294 |
Inhibition, Wnt pathway |
Inhibition, Wnt pathway |
Cellular |
| 1295 |
Defect of Embryogenesis |
Defect of Embryogenesis |
Tissue |
| 1296 |
Increase, insulin |
Increase, insulin |
Molecular |
| 1297 |
Activation, insulin receptor |
Activation, insulin receptor |
Molecular |
| 1298 |
Activation, mTORC2 |
Activation, mTORC2 |
Molecular |
| 1299 |
Activation, AKT |
Activation, AKT |
Molecular |
| 1300 |
Activation, mTORC1 |
Activation, mTORC1 |
Molecular |
| 1301 |
Activation, SREBP-1 |
Activation, SREBP-1 |
Molecular |
| 1302 |
Activation, L-FABP |
Activation, L-FABP |
Molecular |
| 1303 |
Activation, HSD17B4 |
Activation, HSD17B4 |
Molecular |
| 1304 |
Activation, FXR |
Activation, FXR |
Molecular |
| 1305 |
Increase, cytosolic fatty acid |
Increase, cytosolic fatty acid |
Cellular |
| 1306 |
Increased, lipogenesis |
Increased, lipogenesis |
Molecular |
| 1307 |
Inhibition, LXR |
Inhibition, LXR |
Molecular |
| 1308 |
Inhibition, LRH-1 |
Inhibition, LRH-1 |
Molecular |
| 1309 |
Activation, aPKC |
Activation, aPKC |
Molecular |
| 1310 |
Activation, PI3K |
Activation, PI3K |
Molecular |
| 1311 |
Inhibition, Steatosis |
Inhibition, Steatosis |
Organ |
| 1312 |
Increase, Fatty acid beta-oxidation |
Increase, Fatty acid β-oxidation |
Cellular |
| 1313 |
Decrease, cytosolic fatty acid |
Decrease, cytosolic fatty acid |
Molecular |
| 1314 |
Activation, LRH-1 |
Activation, LRH-1 |
Molecular |
| 1315 |
Increase, Selective Serotonin Reuptake Inhibitors (SSRIs) |
Increase, SSRIs |
Molecular |
| 1316 |
Inhibit, serotonin transporter activity |
Inhibit, serotonin transporter activity |
Molecular |
| 1317 |
Decreased, serotonin transporter activity |
Decreased, serotonin transporter activity |
Molecular |
| 1318 |
Decreased, extracellular sodium (Na+) |
Decreased, extracellular Na+ |
Molecular |
| 1319 |
Decreased, extracellular chloride (Cl-) |
Decreased, extracellular chloride (Cl-) |
Molecular |
| 1320 |
Increased, extracellular serotonin |
Increased, extracellular serotonin |
Molecular |
| 1321 |
Increased, intracellular sodium (Na+) |
Increased, intracellular sodium (Na+) |
Molecular |
| 1322 |
Increased, intracellular chloride (Cl-) |
Increased, intracellular chloride (Cl-) |
Molecular |
| 1323 |
Decreased, intracellular serotonin |
Decreased, intracellular serotonin |
Molecular |
| 1324 |
Decreased, packaged serotonin |
Decreased, packaged serotonin |
Molecular |
| 1325 |
Decreased, synaptic release |
Decreased, synaptic release |
Molecular |
| 1326 |
Increased, 5-HT3 (5-hydroxytryptamine) |
Increased, 5-HT3 |
Molecular |
| 1327 |
Decreased, seizure |
Decreased, seizure |
Individual |
| 1328 |
Inactivated, 5-HTR (serotonin receptors) |
Inactivated, 5-HTR |
Molecular |
| 1329 |
Reduce expression, BDNF (Brain-derived neurotrophic factor) |
Reduce expression, BDNF |
Molecular |
| 1330 |
Decreased, neuroplasticity |
Decreased, neuroplasticity |
Molecular |
| 1331 |
Inhibit, agitation |
Inhibit, agitation |
Individual |
| 1332 |
Inhibit, depression |
Inhibit, depression |
Individual |
| 1333 |
Increase, mental stress |
Increase, mental stress |
Individual |
| 1334 |
Increase, cortisone |
Increase, cortisone |
Molecular |
| 1335 |
Reduced, BDNF (Brain-derived neurotrophic factor) |
Reduced, BDNF |
Molecular |
| 1336 |
Activation, 5-HT2A (Serotonin 2A) |
Activation, 5-HT2A |
Molecular |
| 1337 |
Activate, PLC (Phospholipase C) |
Activate, PLC |
Molecular |
| 1338 |
Increase, inositol triphosphate |
Increase, inositol triphosphate |
Molecular |
| 1339 |
Increase, intracellular calcium |
Increase, intracellular calcium |
Cellular |
| 1340 |
Activate, calmodulin |
Activate, calmodulin |
Molecular |
| 1341 |
Increase, myosin light chain phosphorylation |
Increase, myosin light chain phosphorylation |
Molecular |
| 1342 |
Increase, vascular smooth muscle contraction |
Increase, vascular smooth muscle contraction |
Molecular |
| 1343 |
Increase, hypertension |
Increase, hypertension |
Individual |
| 1344 |
Increased, seizure |
Increased, seizure |
Individual |
| 1345 |
Increased, agitation |
Increased, agitation |
Molecular |
| 1346 |
Increased, depression |
Increased, depression |
Individual |
| 1347 |
Decreased, extracellular serotonin |
Decreased, extracellular serotonin |
Molecular |
| 1348 |
Increase, seizure |
Increase, seizure |
Individual |
| 1349 |
Activated, presynaptic neuron 1 |
Activated, presynaptic neuron 1 |
Molecular |
| 1350 |
Increased, glutamate |
Increased, glutamate |
Molecular |
| 1351 |
Activated, NMDA receptor |
Activated, NMDA receptor |
Molecular |
| 1352 |
Activated, voltage-gated sodium channel |
Activated, voltage-gated sodium channel |
Molecular |
| 1353 |
Inhibit, voltage-gated sodium channel |
Inhibit, voltage-gated sodium channel |
Molecular |
| 1354 |
Treat, carbamazepine |
Treat, carbamazepine |
Molecular |
| 1355 |
Activated, membrane depolarization |
Activated, membrane depolarization |
Cellular |
| 1356 |
Inactive, membrane depolarization |
Inactive, membrane depolarization |
Molecular |
| 1357 |
Increased, RDX dose |
Increased, RDX dose |
Molecular |
| 1358 |
Repress, GABA-A receptor |
Repress, GABA-A receptor |
Molecular |
| 1359 |
Activate, GABA-A receptor |
Activate, GABA-A receptor |
Molecular |
| 1360 |
Activate, presynaptic neuron 2 |
Activate, presynaptic neuron 2 |
Molecular |
| 1361 |
Increase, GABA |
Increase, GABA |
Molecular |
| 1362 |
Increased, hippocampal hyperdepolarization |
Increased, hippocampal hyperdepolarization |
Molecular |
| 1363 |
Increased, epilepsy |
Increased, epilepsy |
Individual |
| 1364 |
Increase, Reactive oxygen species |
Increase, ROS |
Molecular |
| 1365 |
Increase, Apoptosis |
Increase, Apoptosis |
Cellular |
| 1366 |
Decrease, Oogenesis |
Decrease, Oogenesis |
Organ |
| 1367 |
Inhibit, gastric ulcer formation |
Inhibit, gastric ulcer formation |
Organ |
| 1368 |
Inhibition, PTGS-1 (Prostaglandin-endoperoxide synthase 1) |
Inhibition, PTGS-1 |
Molecular |
| 1369 |
Activation, PTGS-1 (Prostaglandin-endoperoxide synthase 1) |
Activation, PTGS-1 |
Molecular |
| 1370 |
Activation, PTGS-2 (Prostaglandin-endoperoxide synthase 2) |
Activation, PTGS-2 |
Molecular |
| 1371 |
Inhibition, PTGS-2 (Prostaglandin-endoperoxide synthase 2) |
Inhibition, PTGS-2 (Prostaglandin-endoperoxide synthase 2) |
Molecular |
| 1372 |
Increase, bicarbonate |
Increase, bicarbonate |
Molecular |
| 1373 |
Increase, mucous |
Increase, mucous |
Molecular |
| 1374 |
Increase, mucosal blood flow |
Increase, mucosal blood flow |
Tissue |
| 1375 |
Increase, platelet aggregation |
Increase, platelet aggregation |
Tissue |
| 1376 |
Increase, angiogenesis |
Increase, angiogenesis |
Tissue |
| 1377 |
Decrease, leukocyte adherence |
Decrease, leukocyte adherence |
Tissue |
| 1378 |
Increase, leukocyte adherence |
Increase, leukocyte adherence |
Tissue |
| 1379 |
Activate, leukocyte |
Activate, leukocyte |
Cellular |
| 1380 |
Activate, mucosal defense |
Activate, mucosal defense |
Tissue |
| 1381 |
Increase, surfactant |
Increase, surfactant |
Molecular |
| 1382 |
Decrease, surfactant |
Decrease, surfactant |
Molecular |
| 1383 |
Activate, phospholipase |
Activate, phospholipase |
Molecular |
| 1384 |
Increase, ammonium (NH4+) |
Increase, ammonium (NH4+) |
Molecular |
| 1385 |
Activated, gastric ulcer formation |
Activated, gastric ulcer formation |
Organ |
| 1386 |
CYP7B activity, inhibition |
CYP7B activity, inhibition |
Molecular |
| 1387 |
7α-hydroxypregnenolone synthesis in the brain, decreased |
7α-hydroxypregnenolone synthesis in the brain, decreased |
Cellular |
| 1388 |
Dopamine release in the brain, decreased |
Dopamine release in the brain, decreased |
Tissue |
| 1389 |
Locomotor activity, decreased |
Locomotor activity, decreased |
Individual |
| 1390 |
Sexual behavior, decreased |
Sexual behavior, decreased |
Individual |
| 1391 |
Activation of Cyp2E1 |
Activation of Cyp2E1 |
Molecular |
| 1392 |
Oxidative Stress |
Oxidative Stress |
Molecular |
| 1393 |
Hepatocytotoxicity |
Hepatocytotoxicity |
Cellular |
| 1394 |
Induction, persistent proliferation/sustained proliferation |
Sustained proliferation |
Cellular |
| 1395 |
Liver Cancer |
Liver Cancer |
Organ |
| 1396 |
Increased, glucocorticoid receptor activity |
Increased, glucocorticoid receptor activity |
Molecular |
| 1397 |
Increased, serotonin transporter activity |
Increased, serotonin transporter activity |
Cellular |
| 1398 |
Increased, intracellular serotonin |
Increased, intracellular serotonin |
Cellular |
| 1399 |
Increased, packaged serotonin |
Increased, packaged serotonin |
Cellular |
| 1400 |
Increased, synaptic release |
Increased, synaptic release |
Cellular |
| 1401 |
Decreased, 5-HT3 |
Decreased, 5-HT3 |
Tissue |
| 1402 |
Reduced, PTGS1 function |
Reduced, PTGS1 function |
Molecular |
| 1403 |
Reduced, platelet aggregation |
Reduced, platelet aggregation |
Tissue |
| 1404 |
Decreased, mucosal blood flow |
Decreased, mucosal blood flow |
Tissue |
| 1405 |
Reduced, mucosal defense |
Reduced, mucosal defense |
Tissue |
| 1406 |
Decreased, mucous |
Decreased, mucous |
Tissue |
| 1407 |
Decreased, bicarbonate |
Decreased, bicarbonate |
Tissue |
| 1408 |
Reduced, PTGS2 function |
Reduced, PTGS2 function |
Cellular |
| 1409 |
Decreased, angiogenesis |
Decreased, angiogenesis |
Tissue |
| 1410 |
Increased, leukocyte adherence |
Increased, leukocyte adherence |
Tissue |
| 1411 |
Increased, leukocyte activation |
Increased, leukocyte activation |
Tissue |
| 1412 |
Helicobacter pylori infection |
Helicobacter pylori infection |
Tissue |
| 1413 |
Reduced, presynaptic neuron 2 activity |
Reduced, presynaptic neuron 2 activity |
Cellular |
| 1414 |
Decreased, GABA |
Decreased, GABA |
Cellular |
| 1415 |
Reduced, GABA-A receptor activation |
Reduced, GABA-A receptor activation |
Molecular |
| 1416 |
Decreased, intracellular chloride |
Decreased, intracellular chloride |
Cellular |
| 1417 |
NFE2/Nrf2 repression |
NFE2/Nrf2 repression |
Molecular |
| 1418 |
Increased, steatosis |
Increased, steatosis |
Organ |
| 1419 |
Reduced, FXR activity |
Reduced, FXR activity |
Molecular |
| 1420 |
Reduced, SHP activity |
Reduced, SHP activity |
Molecular |
| 1421 |
Activated, LXR |
Activated, LXR |
Molecular |
| 1422 |
Reduced, PPARalpha |
Reduced, PPARalpha |
Molecular |
| 1423 |
Reduced, HSD17B4 activity |
Reduced, HSD17B4 activity |
Molecular |
| 1424 |
Reduced, fatty acid beta oxidation |
Reduced, fatty acid beta oxidation |
Molecular |
| 1425 |
Mu Opioid Receptor Agonism |
Mu Opioid Receptor Agonism |
Molecular |
| 1426 |
Release of G Proteins |
Release of G Proteins |
Cellular |
| 1427 |
Opening of G protein gated inward rectifying K channels |
Opening of GIRK channels |
Cellular |
| 1428 |
Analgesia |
Analgesia |
Individual |
| 1429 |
Inhibition of N-type Ca ion channels |
Inhibition of Ca Channels |
Cellular |
| 1430 |
Inhibition of neurotransmitter vesicle release |
Inhibition of neurotransmitter release |
Cellular |
| 1431 |
Serotonin 1A Receptor Agonism |
Serotonin 1A Receptor Agonism |
Molecular |
| 1432 |
Anti-depressant Activity |
Anti-depressant Activity |
Individual |
| 1433 |
Increased CGRP, neuronal release of CGRP |
Increased CGRP |
Cellular |
| 1434 |
Irritation of nasal mucosa inducing sneeze reflex |
Irritation induced sneezing |
Tissue |
| 1435 |
Increased neurokinin A (NKA) by neuronal cells |
Increased NKA |
Cellular |
| 1436 |
neurogenic inflammation of sensory nerves |
neurogenic inflammation |
Cellular |
| 1437 |
Sensing of the stressor by pulmonary cells |
Sensing of the stressor |
Molecular |
| 1438 |
Acute phase proteins expression, Increased |
Increased expression of APP |
Organ |
| 1439 |
Systemic acute phase response |
Systemic APR |
Molecular |
| 1440 |
Formation of HDL-SAA |
HDL-SAA formation |
Cellular |
| 1441 |
Increased systemic total cholesterol pool |
Systemic cholesterol increased |
Organ |
| 1442 |
Foam cell formation |
Foam cell formation |
Organ |
| 1443 |
Atherosclerosis |
Atherosclerosis |
Individual |
| 1444 |
Increase, Follicular atresia |
Increase, Follicular atresia |
Organ |
| 1445 |
Increase, Lipid peroxidation |
Increase, LPO |
Molecular |
| 1446 |
Decrease, Coupling of oxidative phosphorylation |
Decrease, Coupling of OXPHOS |
Molecular |
| 1447 |
obesity |
obesity |
Individual |
| 1448 |
activation of CCAAT/enhancer-binding protein alpha |
activation of CEBPA |
Molecular |
| 1449 |
increased adipogenesis |
increased adipogenesis |
Tissue |
| 1450 |
decreased dopamine |
decreased dopamine |
Molecular |
| 1451 |
decreased reward |
decreased reward |
Individual |
| 1452 |
decreased DNA methylation of tyrosine hydroxylase |
decreased DNA methylation of tyrosine hydroxylase |
Cellular |
| 1453 |
decreased methylation of dopamine transporter promoter |
decreased methylation of dopamine transporter promoter |
Cellular |
| 1454 |
chronic high fat diet |
chronic high fat diet |
Individual |
| 1455 |
Incudtion, Sustained inflammatory cytokine release |
Sustained inflammatory cytokine release |
Molecular |
| 1456 |
Increase, Differentiation of fibroblasts |
Differentiation of fibroblasts |
Cellular |
| 1457 |
Induction, Epithelial Mesenchymal Transition |
EMT |
Cellular |
| 1458 |
Pulmonary fibrosis |
Pulmonary fibrosis |
Organ |
| 1459 |
Induction, Cell damage sensing |
Cell damage sensing |
Molecular |
| 1460 |
Increased Substance P (SP) by goblet cells |
SP release |
Cellular |
| 1461 |
DNA double-strand break |
DSB |
Molecular |
| 1462 |
Thiol group of chemicals interact with sulfuhydryl groups of proteins to form thiol adducts |
Thiol protein adducts |
Molecular |
| 1463 |
Inhibition of lysyl oxidase |
Inhibition of lysyl oxidase |
Cellular |
| 1464 |
Reduction of collagen crosslinking |
Reduction of collagen crosslinking |
Tissue |
| 1465 |
Weak collagen matrix |
Weak collagen matrix |
Tissue |
| 1466 |
Notochord distortion or malformations |
Notochord malformation |
Organ |
| 1467 |
Growth, reduction |
Growth, reduction |
Individual |
| 1468 |
Activation, Latent Transforming Growth Factor Beta 1 |
TGFbeta1 activation |
Molecular |
| 1469 |
Activation, Transforming Growth Factor beta pathway |
TGFbeta pathway activation |
Molecular |
| 1470 |
inherited mutations in offspring |
increase in inherited mutations |
Individual |
| 1471 |
Increase, Uncoupling of photophosphorylation |
Increase, Uncoupling of photophosphorylation |
Cellular |
| 1472 |
Decrease, ATP production |
Decrease, ATP production |
Cellular |
| 1473 |
Decrease, Chlorophyll synthesis |
Decrease, Chlorophyll synthesis |
Cellular |
| 1474 |
Decrease, Light harvest capacity |
Decrease, Light harvest capacity |
Cellular |
| 1475 |
Decrease, Photosynthesis |
Decrease, Photosynthesis |
Cellular |
| 1476 |
Decrease, Glycolysis |
Decrease, Glycolysis |
Cellular |
| 1477 |
Decrease, Oxidative phosphorylation |
Decrease, OXPHOS |
Cellular |
| 1478 |
Decrease, Leaf cell mitosis |
Decrease, Leaf cell mitosis |
Tissue |
| 1479 |
Decrease, Leaf development |
Decrease, Leaf development |
Organ |
| 1480 |
Increase, Growth hormone |
Increase, Growth hormone |
Organ |
| 1481 |
Inhibition of mitochondrial DNA polymerase gamma (Pol gamma) |
Inhibition, mitochondrial DNA polymerase gamma (Pol gamma) |
Molecular |
| 1482 |
Depletion, mtDNA |
Depletion, mtDNA |
Cellular |
| 1483 |
Dysfunction, Mitochondria |
Dysfunction, Mitochondria |
Cellular |
| 1484 |
Receptor mediated endocytosis |
Receptor mediated endocytosis |
Molecular |
| 1485 |
Binding of substrate, endocytotic receptor |
Binding of substrate, endocytotic receptor |
Molecular |
| 1486 |
Binding of substrate, endocytic receptor |
Binding of substrate, endocytic receptor |
Molecular |
| 1487 |
Binding, Thiol/seleno-proteins involved in protection against oxidative stress |
Binding, SH/SeH proteins involved in protection against oxidative stress |
Molecular |
| 1488 |
Glutamate dyshomeostasis |
Glutamate dyshomeostasis |
Cellular |
| 1489 |
N/A, Steatohepatisis |
steatohepatitis |
Organ |
| 1490 |
Inhibition, Fatty Acid Beta Oxidation |
Inhibition of fatty acid beta oxidation |
Molecular |
| 1491 |
Increased, Oncotic Necrosis |
increased, oncotic necrosis |
Tissue |
| 1492 |
Tissue resident cell activation |
Tissue resident cell activation |
Cellular |
| 1493 |
Increased Pro-inflammatory mediators |
Increased pro-inflammatory mediators |
Tissue |
| 1494 |
Leukocyte recruitment/activation |
Leukocyte recruitment/activation |
Cellular |
| 1495 |
Substance interaction with the lung resident cell membrane components |
Interaction with the lung cell membrane |
Molecular |
| 1496 |
Increased, secretion of proinflammatory mediators |
Increased proinflammatory mediators |
Cellular |
| 1497 |
Increased, recruitment of inflammatory cells |
Recruitment of inflammatory cells |
Tissue |
| 1498 |
Loss of alveolar capillary membrane integrity |
Loss of alveolar capillary membrane integrity |
Tissue |
| 1499 |
Increased, activation of T (T) helper (h) type 2 cells |
Activation of Th2 cells |
Tissue |
| 1500 |
Increased, fibroblast proliferation and myofibroblast differentiation |
Increased cellular proliferation and differentiation |
Tissue |
| 1501 |
Increased, extracellular matrix deposition |
Increased extracellular matrix deposition |
Tissue |
| 1502 |
Histone deacetylase inhibition |
Histone deacetylase inhibition |
Molecular |
| 1503 |
Histone acetylation, increase |
Histone acetylation, increase |
Cellular |
| 1504 |
p21 (CDKN1A) expression, increase |
p21 (CDKN1A) expression, increase |
Cellular |
| 1505 |
Cell cycle, disrupted |
Cell cycle, disrupted |
Cellular |
| 1506 |
Testicular atrophy |
Testicular atrophy |
Organ |
| 1507 |
Activation of PPARγ |
Activation of PPARγ |
Molecular |
| 1508 |
CYP2E1 Activation |
CYP2E1 Activation |
Molecular |
| 1509 |
Protein Adduct Formation |
Protein Adduct Formation |
Molecular |
| 1510 |
Oxidative Stress in Brain |
Oxidative Stress in Brain |
Molecular |
| 1511 |
Lipid Peroxidation |
Lipid Peroxidation |
Molecular |
| 1512 |
Unfolded Protein Response |
Unfolded Prortein Response |
Molecular |
| 1513 |
General Apoptosis |
General Apoptosis |
Cellular |
| 1514 |
Neurodegeneration |
Neurodegeneration |
Organ |
| 1515 |
Spermatocyte depletion |
Spermatocyte depletion |
Tissue |
| 1516 |
Increase, D1 protein antagonism |
Increase, D1 protein antagonism |
Molecular |
| 1517 |
Decrease, Photosystem II activity |
Decrease, PSII activity |
Molecular |
| 1518 |
Photosynthesis, Decrease |
Photosynthesis |
Cellular |
| 1519 |
Glycolysis |
Glycolysis |
Cellular |
| 1520 |
Oxidative phosphorylation |
OXPHOS |
Cellular |
| 1521 |
Decrease, Growth |
Decrease, Growth |
Individual |
| 1522 |
Inhibition, Chitin synthase 1 |
Inhibition, CHS-1 |
Molecular |
| 1523 |
Decrease, Cuticular chitin content |
Decrease, Cuticular chitin content |
Tissue |
| 1524 |
Increase, Premature molting |
Increase, Premature molting |
Individual |
| 1525 |
Increase, Sulfonylurea receptor binding |
Increase, SUR binding |
Molecular |
| 1526 |
Increase, Opening of voltage-dependent calcium channel |
Increase, Opening of voltage-dependent calcium channel |
Cellular |
| 1527 |
Increase, Cell membrane depolarization |
Increase, Cell membrane depolarization |
Cellular |
| 1528 |
Fatty Acid Beta Oxidation, Decreased |
Fatty Acid Beta Oxidation, Decreased |
Molecular |
| 1529 |
Blockade, L-Type Calcium Channels |
Blockade, L-Type Calcium Channels |
Molecular |
| 1530 |
Decrease, Calcium currents |
Decrease, Calcium currents |
Cellular |
| 1531 |
Decrease, Calcium binding to Troponin C |
Decrease, Calcium binding to Troponin C |
Cellular |
| 1532 |
Decrease, Cardiac contractility |
Decrease, Cardiac contractility |
Organ |
| 1533 |
Decrease, Cardiac ejection fraction |
Decrease, Cardiac ejection fraction |
Organ |
| 1534 |
Decrease, Blood pressure |
Decrease, Blood pressure |
Individual |
| 1535 |
Heart failure |
Heart failure |
Organ |
| 1536 |
Disruption, Intracellular calcium mobilization |
Disruption, Intracellular calcium mobilization |
Cellular |
| 1537 |
Disruption, Sarcomere assembly |
Disruption, Sarcomere assembly |
Cellular |
| 1538 |
Decreased protection against oxidative stress |
Protection against oxidative stress, decreased |
Cellular |
| 1539 |
Endocytotic lysosomal uptake |
endocytosis |
Molecular |
| 1540 |
lysosomal disruption |
lysosom |
Molecular |
| 1541 |
Mitochondrial Complex I inhibition |
Mitochondrial Complex I inhibition |
Molecular |
| 1542 |
Increase, Mitochondrial complex III antagonism |
Increase, Mitochondrial complex III antagonism |
Molecular |
| 1543 |
Mitochondrial Complex IV inhibition |
Mitochondrial Complex IV inhibition |
Molecular |
| 1544 |
Mitochondrial Complex V inhibition |
Mitochondrial Complex V inhibition |
Molecular |
| 1545 |
Decrease in mitochondrial oxidative phosphorylation |
Decrease in mitochondrial oxidative phosphorylation |
Cellular |
| 1546 |
Increased reactive oxygen species (in the mitochondria) |
Increased reactive oxygen species (in the mitochondria) |
Cellular |
| 1547 |
Mitochondrial Injury |
Mitochondrial Injury |
Cellular |
| 1548 |
Necrotic Tissue |
Necrotic Tissue |
Tissue |
| 1549 |
Liver Injury |
Liver Injury |
Organ |
| 1550 |
Deposition of Ionizing Energy |
Ionizing Energy |
Molecular |
| 1551 |
Increase DNA Double Strand Breaks |
DNA DNA double strand breaks |
Molecular |
| 1552 |
Inadequate DNA repair (deprecated, please use https://aopwiki.org/events/155) |
DNA repair |
Molecular |
| 1553 |
Increase mutations |
Increase mutations |
Molecular |
| 1554 |
Increase Chromosomal Aberrations |
Increase chromosomal aberrations |
Molecular |
| 1555 |
Increase cell proliferation |
Increase cell proliferation |
Cellular |
| 1556 |
Increase, lung cancer |
Increase, lung cancer |
Organ |
| 1557 |
Neural crest cell migration, reduced |
Reduced neural crest cell migration |
Cellular |
| 1558 |
Collagen production, reduced |
Reduced collagen production |
Tissue |
| 1559 |
Facial cartilage structures are reduced in size and morphologically distorted |
Smaller and morphologically distorted facial cartilage structures |
Tissue |
| 1560 |
Altered differentiation |
Altered differentiation |
Cellular |
| 1561 |
Neural tube defects |
Neural tube defects |
Tissue |
| 1562 |
Decreased Na/K ATPase activity |
Decreased Na/K ATPase activity |
Cellular |
| 1563 |
Decreased proximal tubular vectorial transport |
Decreased proximal tubular vectorial transport |
Tissue |
| 1564 |
Chemical induced Fanconi syndrome |
Chemical induced Fanconi syndrome |
Individual |
| 1565 |
Suppressed AP-1 |
Suppressed AP-1 |
Cellular |
| 1566 |
Suppressed NF-kB |
Suppressed NF-kB |
Cellular |
| 1567 |
Suppressed DC activation |
Suppressed DC activation |
Organ |
| 1568 |
Impaired antigen presentation |
Impaired antigen presentation |
Organ |
| 1569 |
Impaired T cell activation |
Impaired T cell activation |
Cellular |
| 1570 |
Blocking of IL-1R |
Blocking of IL-1R |
Molecular |
| 1571 |
Decreased IL-1 production |
Decreased IL-1 production |
Cellular |
| 1572 |
Impaired IL-1 signaling |
Impaired IL-1 signaling |
Molecular |
| 1573 |
Suppressed MyD88 |
Suppressed MyD88 |
Cellular |
| 1574 |
Inhibition, IKK complex |
Inhibition, IKK complex |
Molecular |
| 1575 |
Activation, Caspase 8 pathway |
Activation, Caspase 8 pathway |
Molecular |
| 1576 |
Activation, Tissue resident cells (Kuppfer cells) |
Activation, Tissue resident cells (Kuppfer cells) |
Cellular |
| 1577 |
Increased, proinflammatory mediators (TNFalpha) |
Increased, proinflammatory mediators (TNFalpha) |
Molecular |
| 1578 |
Increase, Necrotic tissue |
Increase, Necrotic tissue |
Tissue |
| 1579 |
Increase, proinflammatory mediators (TNFalpha) |
Increase, proinflammatory mediators (TNFalpha) |
Molecular |
| 1580 |
Binding of microtubule stabilizing agents (MSA) to microtubules |
Binding of MSAs to microtubules |
Molecular |
| 1581 |
Disturbance in microtubule dynamic instability |
Disturbance in microtubule dynamic instability |
Cellular |
| 1582 |
Impaired axonial transport |
Impaired axonial transport |
Cellular |
| 1583 |
Sensory axonal peripheral neuropathy |
Sensory axonal peripheral neuropathy |
Individual |
| 1584 |
Interaction of α-diketones with arginine residues |
Interaction of α-diketones with arginine residues |
Molecular |
| 1585 |
Proteasomal dysfunction |
Proteasomal dysfunction |
Molecular |
| 1586 |
Airway epithelial injury |
Airway epithelial injury |
Cellular |
| 1587 |
Fibroproliferative airway lesions |
Fibroproliferative airway lesions |
Tissue |
| 1588 |
Bronchiolitis obliterans |
Bronchiolitis obliterans |
Individual |
| 1589 |
Systemic or topical administration of chemicals |
Administration of chemicals |
Molecular |
| 1590 |
Distribution and deposition of chemicals to skin and/or eyes |
Distribution of chemicals |
Molecular |
| 1591 |
Absorption of photon energy |
Absorption of photon energy |
Molecular |
| 1592 |
ROS generation from photoactivated chemicals |
ROS generation |
Molecular |
| 1593 |
Radicals of target chemicals |
Radical generation |
Molecular |
| 1594 |
Oxidation of membrane lipids |
Oxidation of membrane lipids |
Cellular |
| 1595 |
Oxidation/denatuation of membrane proteins |
Oxidation/denatuation of membrane proteins |
Cellular |
| 1596 |
Oxidation of DNA |
Oxidation of DNA |
Cellular |
| 1597 |
Formation of DNA photo-adducts |
DNA photo-adducts |
Cellular |
| 1598 |
Formation of protein photo-adducts |
Protein photo-adducts |
Cellular |
| 1599 |
Inflamatory events in light-exposed tissues |
Inflammatory events |
Organ |
| 1600 |
Eczematous eruption (Erythema, Papules, Vesicles, Pruritius, Weeping, Oozing, Crusting) |
Eczematous eruption |
Organ |
| 1601 |
Scaling, Lichenification |
Scaling, Lichenification |
Organ |
| 1602 |
Activation, Muscarinic Acetylcholine Receptors |
Activation, Muscarinic Acetylcholine Receptors |
Molecular |
| 1603 |
Chronic kidney disease |
Chronic kidney disease |
Organ |
| 1604 |
Inhibition of N-linked glycosylation |
Inhibition of N-linked glycosylation |
Molecular |
| 1605 |
Accumulation of misfolded proteins |
Accumulation, misfolded proteins |
Cellular |
| 1606 |
Activation of hepatic stellate cells |
Activation, hepatic stellate cells |
Cellular |
| 1607 |
Increase, Necrosis |
Increase, Necrosis |
Tissue |
| 1608 |
Increase, Oxidative DNA damage |
Increase,Oxidative DNA damage |
Molecular |
| 1609 |
Inhibition, Cytochrome P450 enzyme (CYP17A1) activity |
Inhibition of Cyp17A1 activity |
Molecular |
| 1610 |
Reduction, 17-OH-pregnenolone conversion in DHEA |
Reduction, DHEA |
Cellular |
| 1611 |
Reduction, 17-OH-progesterone conversion in androstenedione |
Reduction, androstenedione |
Cellular |
| 1612 |
Decrease, testosterone synthesis/level |
Decrease, testosterone level |
Cellular |
| 1613 |
Decrease, dihydrotestosterone (DHT) level |
Decrease, DHT level |
Cellular |
| 1614 |
Decrease, androgen receptors (AR) activation |
Decrease, AR activation |
Cellular |
| 1615 |
Impaired inguinoscrotal testicular descent phase |
Impaired inguinoscrotal phase |
Organ |
| 1616 |
Malformation, cryptorchidism - maldescended testis |
Malformation, cryptorchidism |
Organ |
| 1617 |
5α-reductase, inhibition |
5α-reductase, inhibition |
Molecular |
| 1618 |
Reduction, egg production and spawning |
Reduction, egg production and spawning |
Individual |
| 1619 |
Increase, DNA methyltransferase inhibition |
Increase, DNMT inhibition |
Molecular |
| 1620 |
Increase, DNA hypomethylation |
Increase, DNA hypomethylation |
Molecular |
| 1621 |
Increase, Gene expression |
Increase, Gene expression |
Molecular |
| 1622 |
Decrease, Transgenerational DNA methylation |
Decrease, Transgenerational DNA methylation |
Molecular |
| 1623 |
Occurrence, Focal Seizure |
Occurrence, Focal Seizure |
Tissue |
| 1624 |
Tyrosinase inhibition leads to L-Dopaquinone reduction |
tyrosinase, L-Dopaquinone reduction |
Molecular |
| 1625 |
Reduction of L-Dopaquinone leads to melanin reduction |
melanin |
Cellular |
| 1626 |
reduction in melanin lead to decrease of pigmentation |
melanin, pigmentation |
Tissue |
| 1627 |
Inhibition of tyrosinase |
tyrosinase |
Molecular |
| 1628 |
Reduction of L-Dopaquinone |
Reduction of L-Dopaquinone |
Cellular |
| 1629 |
Reduction in melanin level |
Reduction in melanin level |
Cellular |
| 1630 |
Reduction of melanosome level |
Reduction of melanosome level |
Tissue |
| 1631 |
Reduction fo Pigmentation pattern |
Reduction fo Pigmentation pattern |
Individual |
| 1632 |
Increase in reactive oxygen and nitrogen species (RONS) |
Increase in RONS |
Molecular |
| 1633 |
Increase in inflammation |
Increase in inflammation |
Tissue |
| 1634 |
Increase, Oxidative damage to DNA |
Increase, Oxidative DNA damage |
Molecular |
| 1635 |
Increase, DNA strand breaks |
Increase, DNA strand breaks |
Molecular |
| 1636 |
Increase, Chromosomal aberrations |
Increase, Chromosomal aberrations |
Cellular |
| 1637 |
Retinaldehyde dehydrogenase inhibition |
Retinaldehyde dehydrogenase |
Molecular |
| 1638 |
Retinoic acid (RA) synthesis decreased |
RA |
Cellular |
| 1639 |
Plasma RA level decreased |
Plasma RA |
Tissue |
| 1640 |
Altered, Photoreceptor patterning |
Altered, Photoreceptor patterning |
Cellular |
| 1641 |
Decreased retinoic acid (RA) synthesis |
retinoic acid |
Cellular |
| 1642 |
Decreased plasma RA level |
plasma retionic acid |
Tissue |
| 1643 |
Altered, Visual function |
Altered, Visual function |
Organ |
| 1644 |
Impaired Ab production |
Impaired Ab production |
Cellular |
| 1645 |
Wnt ligand stimulation |
Wnt ligand stimulation |
Molecular |
| 1646 |
Frizzled activation |
Frizzled activation |
Molecular |
| 1647 |
GSK3beta inactivation |
GSK3beta inactivation |
Molecular |
| 1648 |
β-catenin activation |
β-catenin activation |
Molecular |
| 1649 |
Snail, Zeb, Twist activation |
Snail, Zeb, Twist activation |
Molecular |
| 1650 |
Epithelial-mesenchymal transition |
Epithelial-mesenchymal transition |
Tissue |
| 1651 |
Treatment-resistant gastric cancer |
Resistant gastric cancer |
Tissue |
| 1652 |
Increase, S-adenosylmethionine depletion |
Increase, SAM depletion |
Molecular |
| 1653 |
Binding of inhibitor to mitochondrial complex III |
Binding of inhibitor, mitochondrial complex III |
Molecular |
| 1654 |
Binding of inhibitor to mitochondrial complex IV |
Binding of inhibitor, mitochondrial complex IV |
Molecular |
| 1655 |
Binding of inhibitor to mitochondrial complex V |
Binding of inhibitor, mitochondrial complex V |
Molecular |
| 1656 |
Antagonism, Thyroid Receptor |
TR Antagnoism |
Molecular |
| 1657 |
Inhibition of cystathionine beta-synthase |
CBS inhibition |
Molecular |
| 1658 |
Inhibition of Methionine synthase |
Methionine synthase |
Molecular |
| 1659 |
Inhibition of Methylenetetrahydrofolate reductase |
MTHFR inhibition |
Molecular |
| 1660 |
Inhibition of betaine-homocysteine methyltransferase |
betaine-homocysteine methyltransferase inhibition |
Molecular |
| 1661 |
Increased Homocysteine level |
Homocysteine increases |
Cellular |
| 1662 |
Increased plasma Homocysteine level |
plasma homocysteine increases |
Tissue |
| 1663 |
Increased brain Homocysteine level |
brain Homocysteine level increases |
Organ |
| 1664 |
Induce Neuronal dysfunctions |
Neuronal dysfunctions induction |
Individual |
| 1665 |
Increased, Plasma HCY level |
Plasma HCY level |
Tissue |
| 1666 |
Induced, dysfunction of microcirculation |
dysfunction of microcirculation |
Organ |
| 1667 |
Impaired,anterior-posterior axis development |
anterior-posterior axis development |
Individual |
| 1668 |
Frustrated phagocytosis |
Frustrated phagocytosis |
Cellular |
| 1669 |
Increased, DNA damage and mutation |
Increased, DNA damage and mutation |
Cellular |
| 1670 |
Lung cancer |
Lung cancer |
Organ |
| 1671 |
Substance - lung surfactant interaction |
Substance - LS interaction |
Molecular |
| 1672 |
Inhibition of lung surfactant function |
Inhibition of LS function. |
Molecular |
| 1673 |
Alveolar collapse |
Alveolar collapse |
Cellular |
| 1674 |
Alveolar reopening |
Alveolar reopening |
Tissue |
| 1675 |
Loss of barrier function |
Loss of barrier function |
Tissue |
| 1676 |
Blood extravasation into the lungs |
Blood extravasation into the lungs |
Organ |
| 1677 |
Reduced tidal volume |
Reduced tidal volume |
Organ |
| 1678 |
Impaired oxygenation of the blood |
Impaired oxygenation of the blood |
Organ |
| 1679 |
Acute inhalation toxicity |
Acute inhalation toxicity |
Individual |
| 1680 |
Inhibition, TBX1 |
Inhibition, TBX1 |
Molecular |
| 1681 |
Disruption, Neural crest cell migration |
Disruption, Neural crest cell migration |
Cellular |
| 1682 |
Disruption, Progenitor cells of second heart field |
Disruption, Progenitor cells of second heart field |
Cellular |
| 1683 |
Impairment, Fourth pharyngeal arch development |
Impairment, Fourth pharyngeal arch development |
Tissue |
| 1684 |
Abnormalities, Cardiac outflow tract formation |
Abnormalities, Cardiac outflow tract formation |
Organ |
| 1685 |
Anomalies, Congenital cardiac conotruncal |
Anomalies, Congenital cardiac conotruncal |
Individual |
| 1686 |
Deposition of Energy |
Energy Deposition |
Molecular |
| 1687 |
decrease, transcription of genes by AR |
decrease, transcription of genes by AR |
Cellular |
| 1688 |
anogenital distance (AGD), decreased |
AGD, decreased |
Tissue |
| 1689 |
decrease, testosterone synthesis |
decrease, testosterone synthesis |
Cellular |
| 1690 |
reduction, testosterone levels |
reduction, testosterone levels |
Tissue |
| 1691 |
Antagonism,LH receptor |
Antagonism,LH receptor |
Molecular |
| 1692 |
Reduction, Progesterone synthesis |
Reduction, Progesterone synthesis |
Cellular |
| 1693 |
Reduction, Plasma progesterone concentration |
Reduction, Plasma progesterone concentration |
Tissue |
| 1694 |
Reduction, progesterone uptake, decresed maturation |
Reduction, progesterone uptake, decresed maturation |
Cellular |
| 1695 |
Impaired ovulation |
Impaired ovulation |
Organ |
| 1696 |
Decrease of egg production and cummulative fecundity |
Decrease of egg production and cummulative fecundity |
Individual |
| 1697 |
Increase, DNA methyltransferase expression |
Increase, DNMT expression |
Molecular |
| 1698 |
Increase, hypermethylation of the promotor region of gonadotropin releasing hormone receptor |
Increase, hypermethylation of the promotor region of GnRHR |
Molecular |
| 1699 |
Decrease, expression of gonadotropin releasing hormone receptor |
Decease, expression of GnRHR |
Molecular |
| 1700 |
Impaired IL-1R1 signaling in T cell |
Impaired IL-1R1 signaling |
Molecular |
| 1701 |
Suppression of NF-kB |
Suppression of NF-kB |
Molecular |
| 1702 |
Suppression of T cell activation |
Suppression of T cell activation |
Cellular |
| 1703 |
Dysregulation of heart rate and vascular tone |
Cardiovascular dysregulation |
Organ |
| 1704 |
testJF |
test |
Molecular |
| 1705 |
Impaired coordination and movement |
Impaired coordination and movement |
Individual |
| 1706 |
Stimulation, TLR7/8 |
Stimulation of TLR7/8 |
Molecular |
| 1707 |
Increase, IL-23 from matured dendritic cells |
Increase of IL-23 |
Cellular |
| 1708 |
Th17 cell migration and inflammation induction |
Th17 cell migration and inflammation induction |
Cellular |
| 1709 |
Psoriatic skin disease |
Skin disease |
Individual |
| 1710 |
Binding to estrogen receptor (ER)-α in immune cells |
Binding to estrogen receptor (ER)-α |
Molecular |
| 1711 |
Induction of GATA3 expression |
Induction of GATA3 expression |
Cellular |
| 1712 |
Increase of Th2 cells producing IL-4 |
Increase of Th2 cells producing IL-4 |
Cellular |
| 1713 |
Increase of anti-DNA antibody from autoreactive B cell |
Increase of autoantibody production |
Cellular |
| 1714 |
Exacerbation of systemic lupus erythematosus (SLE) |
Exacerbation of SLE |
Individual |
| 1715 |
Inhibition of JAK3 |
Inhibition of JAK3 |
Molecular |
| 1716 |
Blockade of STAT5 phosphorylation |
STAT5 inhibition |
Cellular |
| 1717 |
Suppression of STAT5 binding to cytokine gene promoters |
Suppression of STAT5 binding to cytokine gene promoters |
Cellular |
| 1718 |
Suppression of IL-4 production |
Suppression of IL-4 production |
Cellular |
| 1719 |
Impairment of T-cell dependent antibody response |
Impairment, TDAR |
Individual |
| 1720 |
Trypsin inhibition |
Inhibition, trypsin |
Molecular |
| 1721 |
Increased intestinal monitor peptide level |
Increased monitor peptide |
Organ |
| 1722 |
Increased blood CCK level |
Increased blood CCK level |
Organ |
| 1723 |
Increased exocrine secretion from pancreatic acinar cells |
Increased acinar cell exocrine secretion |
Cellular |
| 1724 |
Acinar cell proliferation |
Acinar cell proliferation |
Cellular |
| 1725 |
Pancreatic acinar cell tumors |
Acinar cell tumors |
Molecular |
| 1738 |
SARS-CoV-2 cell entry |
SARS-CoV-2 cell entry |
Cellular |
| 1739 |
Binding to ACE2 |
Binding to ACE2 |
Molecular |
| 1740 |
Induced dysregulation of ACE2 |
ACE2 enzymatic inhibition |
Molecular |
| 1741 |
Induced, Angiotensin (Ang) II accumulation |
Induced, Angiotensin (Ang) II accumulation |
Tissue |
| 1743 |
Increase plasma Ang II |
Increase plasma Ang II |
Tissue |
| 1745 |
Increase,collagen synthesis |
Increase,collagen synthesis |
Cellular |
| 1746 |
Induction lung fibrosis |
Induction lung fibrosis |
Organ |
| 1748 |
Increase, the risk of acute respiratory failure |
Increase, the risk of acute respiratory failure |
Organ |
| 1750 |
Increased inflammatory immune responses |
Increased inflammatory immune responses |
Tissue |
| 1751 |
Decreased mortality |
Decreased mortality |
Individual |
| 1752 |
Increased Angiotensin II |
Increased AngII |
Cellular |
| 1753 |
Chronic reactive oxygen species |
Chronic ROS |
Molecular |
| 1754 |
Porcupine-induced Wnt secretion and Wnt signaling activation |
Porcupine-induced Wnt secretion and Wnt signaling activation |
Cellular |
| 1755 |
beta-catenin activation |
beta-catenin activation |
Cellular |
| 1756 |
Decreased, plasma 11-ketotestosterone level |
Decreased, 11KT |
Tissue |
| 1757 |
Reduce, Sperm count |
Reduce, Sperm count |
Individual |
| 1758 |
Impaired, Spermatogenesis |
Impaired, Spermatogenesis |
Organ |
| 1759 |
Increase, Cripto-1 expression |
Increase, Cripto-1 expression |
Cellular |
| 1760 |
Inhibition, Activin signaling |
Inhibition, Activin signaling |
Cellular |
| 1761 |
Inhibition, Fin regeneration |
Inhibition, Fin regeneration |
Tissue |
| 1762 |
Urothelial cell injury/death |
cell injury |
Cellular |
| 1763 |
Urothelial Tumor |
carcinogenicity |
Organ |
| 1765 |
Increase, Formation of DNA photoproducts |
Increase, Formation of DNA photoproducts |
Molecular |
| 1766 |
Increase, DNA double-strand break |
Increase, DNA DSB |
Molecular |
| 1767 |
Increase, Protein oxidation |
Increase, Protein oxidation |
Molecular |
| 1768 |
Increase, Abnormal osmoregulation |
Increase, Abnormal osmoregulation |
Tissue |
| 1769 |
Increase, Body fluid overload |
Increase, Body fluid overload |
Tissue |
| 1770 |
Decrease, Mitochondrial membrane potential |
Decrease, MMP |
Cellular |
| 1771 |
Decrease, Adenosine triphosphate pool |
Decrease, ATP pool |
Cellular |
| 1772 |
Decrease, Neutral lipids |
Decrease, Neutral lipids |
Tissue |
| 1773 |
Decrease, Global DNA methylation |
Decrease, Global DNA methylation |
Molecular |
| 1774 |
Increase, Caspase transcription |
Increase, Casp transcription |
Molecular |
| 1775 |
Increase, Oocyte apoptosis |
Increase, Oocyte apoptosis |
Cellular |
| 1776 |
Increase, Ovarian somatic cell apoptosis |
Increase, Ovarian somatic cell apoptosis |
Cellular |
| 1777 |
Increase, Ovarian follicle breakdown |
Increase, Ovarian follicle breakdown |
Organ |
| 1778 |
Decrease, Heritable DNA methylation (F3) |
Decrease, Heritable DNA methylation (F3) |
Molecular |
| 1779 |
Increase, Caspase transcription (F3) |
Increase, Casp transcription (F3) |
Molecular |
| 1780 |
Increase, Oocyte apoptosis (F3) |
Increase, Oocyte apoptosis (F3) |
Cellular |
| 1781 |
Decrease, Fecundity (F3) |
Decrease, Fecundity (F3) |
Individual |
| 1782 |
Decrease, Oogenesis (F3) |
Decrease, Oogenesis (F3) |
Organ |
| 1783 |
Increase, Ovarian somatic cell apoptosis (F3) |
Increase, Ovarian somatic cell apoptosis (F3) |
Cellular |
| 1784 |
Increase, Ovarian follicle breakdown (F3) |
Increase, Ovarian follicle breakdown (F3) |
Organ |
| 1785 |
Increase, Mitochondrial ATP synthase antagonism |
Increase, Mitochondrial ATP synthase antagonism |
Molecular |
| 1786 |
Nipple retention (NR), increased |
nipple retention, increased |
Individual |
| 1787 |
Downregulation, ACE2 |
Downregulation of ACE2 |
Cellular |
| 1788 |
Status epilepticus |
Status epilepticus |
Individual |
| 1789 |
Reduction, 17beta-estradiol synthesis by the undifferentiated gonad |
Reduction, E2 Synthesis by the undifferentiated gonad |
Cellular |
| 1790 |
Increased, Differentiation to Testis |
Increased, Differentiation to Testis |
Tissue |
| 1791 |
Increased, Male Biased Sex Ratio |
Increased, Male Biased Sex Ratio |
Population |
| 1792 |
Toll-like receptor 4 activation |
TLR4 activation |
Molecular |
| 1793 |
Activator protein 1 activation |
AP-1 activation |
Cellular |
| 1794 |
Pin-1 activation |
Pin-1 activation |
Cellular |
| 1795 |
Latent Transforming growth Factor beta expression |
TGFbeta expression |
Cellular |
| 1796 |
11β-hydroxylase inhibition |
11β-hydroxylase inhibition |
Molecular |
| 1798 |
Decreased spermatogenesis |
Decreased spermatogenesis |
Organ |
| 1799 |
Inhibition of 11β-HSD |
Inhibition of 11β-HSD |
Molecular |
| 1800 |
Granulosa cell proliferation of gonadotropin-independent follicles, Reduced |
Reduced granulosa cell proliferation |
Cellular |
| 1801 |
Thyroperoxidase inhibition |
TPO inhibition |
Molecular |
| 1806 |
Inhibition, Chitinase |
Inhibition, Chitinase |
Molecular |
| 1807 |
Inhibition, Chitobiase |
Inhibition, Chitobiase |
Molecular |
| 1808 |
Decrease, ATP synthase activity |
Decrease, ATP synthase activity |
Molecular |
| 1809 |
Increase, Tissue/organ damage |
Increase, Tissue/organ damage |
Organ |
| 1810 |
Decrease, Plasma membrane ATPase activity |
Decrease, ATPase activity |
Cellular |
| 1811 |
Increase, Mitochondrial complex III dysfunction |
Increase, Complex III dysfunction |
Molecular |
| 1812 |
Increase, Cytochrome c release |
Increase, Cyt c release |
Cellular |
| 1813 |
Increase, Mitochondrial complex I dysfunction |
Increase, Complex I dysfunction |
Molecular |
| 1814 |
benzoquinone imine and acylglucuronide metabolites |
Reactive Metabolite |
Molecular |
| 1815 |
Activation of ER stress |
ER stress |
Cellular |
| 1816 |
Mitochondrial dysfunction |
Mitochondrial dysfunction |
Cellular |
| 1817 |
Apoptotic cell death |
Apoptotic cell death |
Cellular |
| 1818 |
Immune cell activation |
Immune cell activation |
Cellular |
| 1819 |
IFNγ signaling |
IFNγ signaling |
Cellular |
| 1820 |
Immune mediated hepatitis |
hepatitis |
Organ |
| 1821 |
Decrease, Cell proliferation |
Decrease, Cell proliferation |
Cellular |
| 1822 |
Maturation of TNF/iNOS-Producing Dendritic Cells |
Maturation, TNF/iNOS-Producing Dendritic Cells |
Cellular |
| 1823 |
Decrease, Lipid storage |
Decrease, Lipid storage |
Cellular |
| 1824 |
Decrease, Fatty acid β-oxidation |
Decrease, FAO |
Cellular |
| 1825 |
Increase, Cell death |
Increase, Cell death |
Cellular |
| 1826 |
Increase, Oxygen consumption |
Increase, Oxygen consumption |
Cellular |
| 1827 |
Increase, Global DNA methylation |
Increase, Global methylation |
Molecular |
| 1828 |
Increased, Thyroxine (T4) in serum |
Increased, Thyroxine (T4) in serum |
Organ |
| 1829 |
Altered, Thyroid hormone-dependent gene expression |
Altered, TH-dependent gene expression |
Molecular |
| 1830 |
Displacement, Serum thyroxine (T4) from carrier protein |
Displacement, Serum thyroxine (T4) from carrier protein |
Molecular |
| 1831 |
Binding, Thyroid binding globulin in serum |
Binding, Thyroid binding globulin in serum |
Molecular |
| 1832 |
Coordinated gene expression changes by PPARα activation |
Coordinated gene expression changes |
Molecular |
| 1833 |
Impaired lung function |
Impaired lung function |
Individual |
| 1834 |
Decrease, Acyl-CoA dehydrogenases |
Decrease, ACAD |
Molecular |
| 1835 |
Cortisol and 11β-(OH) testosterone decreased |
Cortisol and 11β-(OH) testosterone decreased |
Cellular |
| 1836 |
Decreased plasma Cortisol level |
Decreased plasma Cortisol level |
Tissue |
| 1837 |
decreased oocyte maturation |
decreased oocyte maturation |
Organ |
| 1839 |
Testicular Cancer |
Testicular Cancer |
Organ |
| 1840 |
Inhibition, cytochrome oxidase |
Inhibition, cytochrome oxidase |
Molecular |
| 1841 |
Encephalitis |
Encephalitis |
Organ |
| 1842 |
Prolonged TLR9 activation |
TLR9 activation |
Molecular |
| 1843 |
Multi Organ Failure involving Acute Respiratory Distress Syndrome |
ARDS and MODS |
Individual |
| 1844 |
systemic inflammatory response syndrome |
SIRS |
Individual |
| 1845 |
Coagulation |
Coagulation |
Organ |
| 1846 |
Thrombosis and Disseminated Intravascular Coagulation |
Thrombosis and DIC |
Individual |
| 1847 |
Increased SARS-CoV-2 production |
SARS-CoV-2 production |
Cellular |
| 1848 |
Toll Like Receptor (TLR) Dysregulation |
TLR Activation/Dysregulation |
Molecular |
| 1849 |
Impaired gustatory nerve |
Impaired gustatory nerve |
Tissue |
| 1850 |
dysgeusia |
taste impairment |
Organ |
| 1851 |
Binding of agonist, Angiotensin II receptor type 1 receptor (AT1R) |
Binding of agonist, Angiotensin II receptor type 1 receptor (AT1R) |
Molecular |
| 1852 |
Increased Ang II type 1 receptor (AT1R) |
Increased Ang II type 1 receptor (AT1R) |
Tissue |
| 1853 |
Hyperactivation of ACE/Ang-II/AT1R axis |
Hyperactivation of ACE/Ang-II/AT1R axis |
Molecular |
| 1854 |
Dysregulation, ACE2 expression and activity |
ACE2 dysregulation |
Molecular |
| 1855 |
Increased Sodium-sensitive hypertension |
Increased Sodium-sensitive hypertension |
Tissue |
| 1856 |
Imbalanced salty and sweet taste responses |
Sodium inhibition, Sweet enhancement |
Tissue |
| 1857 |
Platelet-neutrophil interactions, Increased |
Platelet-neutrophil interactions, Increased |
Cellular |
| 1858 |
Increased viral transcription and replication |
Increased viral transcription and replication |
Cellular |
| 1859 |
Excitation of intracellular water |
Excitation of intracellular water |
Molecular |
| 1860 |
Increase, Excitation of intracellular water |
Excitation of intracellular water |
Molecular |
| 1861 |
Increase, D1 protein deactivation |
D1 protein deactivation |
Cellular |
| 1862 |
Decrease, Photosystem II efficiency |
Decrease, Photosystem II efficiency |
Cellular |
| 1863 |
Decrease, Reproduction |
Decrease, Reproduction |
Individual |
| 1864 |
Increase, Programmed cell death |
Increase, Programmed cell death |
Cellular |
| 1865 |
Increase, Oxygen-evolving complex damage |
Increase, OEC damage |
Molecular |
| 1866 |
Fibrinolysis, decreased |
Hypofibrinolysis |
Molecular |
| 1867 |
Bradykinin system, hyperactivated |
Bradykinin, activated |
Molecular |
| 1868 |
Hyperinflammation |
Hyperinflammation |
Tissue |
| 1869 |
Diminished protective oxidative stress response |
Diminished Protective Response to ROS |
Cellular |
| 1870 |
Sustentacular cells, decrease |
Sustentacular cells, decrease |
Cellular |
| 1871 |
olfactory sensory neurons, decrease |
olfacotry neurons, decrease |
Cellular |
| 1872 |
Olfactory epithelium degeneration |
Olfactory epithelium degeneration |
Tissue |
| 1873 |
impaired olfactory function (anosmia) |
anosmia |
Organ |
| 1874 |
blood brain barrier disruption |
BBB disruption |
Cellular |
| 1875 |
Cerebrovascular disease (stroke) |
stroke |
Organ |
| 1876 |
ACE2 shedding effects on viral entry |
Hyunjoon Kong |
Cellular |
| 1877 |
Altered, retinal layer structure |
Altered, retinal layer structure |
Tissue |
| 1878 |
Decreased, Eye size |
Decreased, Eye size |
Organ |
| 1879 |
Bulky DNA adducts, increase |
Bulky DNA adducts, increase |
Molecular |
| 1880 |
Inhibition of ALDH1A (RALDH) |
ALDH1A (RALDH), inhibition |
Molecular |
| 1881 |
Decreased, all-trans retinoic acid (atRA) concentration |
Decreased, atRA concentration |
Tissue |
| 1882 |
Disrupted meiotic initiation of fetal oogonia of the ovary |
Oocyte meiosis, disrupted |
Cellular |
| 1883 |
Reduced size of the ovarian follicle pool |
Ovarian follicle pool, reduced |
Organ |
| 1884 |
Inhibition of Fyna |
Inhibition of Fyna |
Molecular |
| 1885 |
Inhibition of Plxna2 |
Inhibition of Plxna2 |
Molecular |
| 1886 |
Overexpression of rasl11b |
Overexpression of rasl11b |
Molecular |
| 1887 |
Inhibition of CYP26B1 activity |
CYP26B1, inhibition |
Molecular |
| 1888 |
Increased (ectopic) all-trans retinoic acid concentration |
increased atRA concentration |
Tissue |
| 1889 |
Premature initiation of meiosis in fetal male germ cells |
premature meiosis, male germ cells |
Cellular |
| 1890 |
Decrease (loss of) fetal male germ cells |
Germ cell loss, male |
Cellular |
| 1891 |
abnormal, placental labyrinth vasculature morphology |
abnormal, placental labyrinth vasculature morphology |
Tissue |
| 1892 |
increase, placental insufficiency |
increase, placental insufficiency |
Organ |
| 1893 |
increase, Preeclampsia |
increase, Preeclampsia |
Individual |
| 1894 |
chronic low grade systemic inflammation |
low grade inflammation |
Individual |
| 1895 |
NLRP3 inflammasome activity, increased |
inflammasome activity, increased |
Molecular |
| 1896 |
Genomic instability |
Genomic instability |
Cellular |
| 1897 |
increased MyD88 activation |
MyD88 activation |
Molecular |
| 1898 |
increased release of danger/damage associated molecular patterns |
increased release of DAMPS |
Tissue |
| 1899 |
formation of neutrophil extracellular traps (NETs) |
NETosis |
Cellular |
| 1900 |
increased platelet surface TLR9 expression |
increased platelet tlr9 expression |
Cellular |
| 1901 |
Interferon-I antiviral response, antagonized by SARS-CoV-2 |
IFN-I response, antagonized |
Cellular |
| 1902 |
Repression of Gbx2 expression |
Repression of Gbx2 expression |
Molecular |
| 1903 |
foxi1 expression, increased |
foxi1 expression, increased |
Molecular |
| 1904 |
six1b expression, increased |
six1b expression, increased |
Molecular |
| 1905 |
eya1 expression, inhibited |
eya1 expression, inhibited |
Molecular |
| 1906 |
Cystic Fibrosis Transmembrane Regulator Function, Decreased |
CFTR Function, Decreased |
Molecular |
| 1907 |
Airway Surface Liquid Height, Decreased |
ASL Height, Decreased |
Tissue |
| 1908 |
Cilia Beat Frequency, Decreased |
CBF, Decreased |
Cellular |
| 1909 |
Mucociliary Clearance, Decreased |
MCC, Decreased |
Individual |
| 1910 |
Mucus Viscosity, Increased |
Mucus Viscosity, Increased |
Organ |
| 1911 |
FOXJ1 Protein, Decreased |
FOXJ1 Protein, Decreased |
Cellular |
| 1912 |
Motile Cilia Number/Length, Decreased |
Motile Cilia Number/Length, Decreased |
Cellular |
| 1913 |
Endothelial cell dysfunction |
Endothelial cell dysfunction |
Cellular |
| 1914 |
Platelet activation, Increased |
Platelet activation, Increased |
Cellular |
| 1915 |
Neutrophil activation, Increased |
Neutrophil activation, Increased |
Cellular |
| 1916 |
Thromboinflammation, Increased |
Thromboinflammation, Increased |
Organ |
| 1917 |
Altered gene expression, NRF2 dependent antioxidant pathway |
Altered expression of NRF2 pathway-dependent genes |
Molecular |
| 1918 |
Increased，Myocardial apoptosis |
Increased，Myocardial apoptosis |
Cellular |
| 1919 |
Increased，Cardiac Dysregulation |
Increased，Cardiac dysfunction |
Tissue |
| 1920 |
Altered gene expression, TGF-β dependent fibrosis pathway |
Altered expression of TGF-β fibrosis pathway-dependent genes |
Molecular |
| 1921 |
Altered gene expression, NF-kB dependent Interleukin-6 pathway |
Altered expression of IL-6 pathway-dependent genes |
Molecular |
| 1922 |
Increased, Reactive metabolites production |
Increased, metabolites |
Cellular |
| 1923 |
Altered gene expression, P53 dependent apoptosis pathway |
Altered expression of P53 pathway-dependent genes |
Molecular |
| 1924 |
Increased，Cardiac fibrosis |
Increased，Cardiac fibrosis |
Organ |
| 1925 |
Increased，Vascular smooth muscle cell activation |
Increased，Vascular smooth muscle cell activation |
Cellular |
| 1926 |
Increased，Vascular fibrosis |
Increased，Vascular fibrosis |
Tissue |
| 1927 |
Increased，Vascular endothelial cell autophagy dysfunction |
Increased，Vascular endothelial cell autophagy dysfunction |
Cellular |
| 1928 |
increased，Vascular endothelial dysfunction |
increased，Vascular endothelial dysfunction |
Tissue |
| 1929 |
Increased incidence of cardiovascular morbidity and mortality in the general population |
Increased incidence of cardiovascular morbidity and mortality |
Population |
| 1930 |
altered, inner ear development |
Altered, inner ear development |
Organ |
| 1931 |
Intestinal barrier, disruption |
Disruption of the intestinal barrier |
Organ |
| 1932 |
Gastrointestinal disorders |
GI disorders |
Individual |
| 1933 |
Increased, Interleukin-6 production |
Increased IL-6 production |
Cellular |
| 1934 |
Myocardial Infarction |
Heart attack |
Organ |
| 1935 |
Angiotensin (1-7) levels diminished |
Ang (1-7) levels reduced |
Molecular |
| 1936 |
Angiotensin II degradation reduced |
Degradation of Ang-II reduced |
Molecular |
| 1937 |
ADAM17 expression induction |
ADAM17 induction |
Cellular |
| 1938 |
ACE2 increased shedding |
ACE2 increased shedding |
Molecular |
| 1939 |
Viral infection and host-to-host transmission, proliferated |
Viral infection, proliferated |
Individual |
| 1940 |
Increases in cellular reactive oxygen species |
Increases in cellular ROS |
Molecular |
| 1941 |
Memory Loss |
Memory Loss |
Individual |
| 1942 |
Accumulation, Cytosolic toxic Tau oligomers |
Accumulation, Toxic Tau oligomers |
Cellular |
| 1943 |
Hyperphosphorylation of Tau |
p-Tau |
Cellular |
| 1944 |
Synaptic dysfunction |
Dysfunctional synapses |
Organ |
| 1945 |
Dysfunctional Autophagy |
Dysfunctional autophagy |
Cellular |
| 1946 |
Impaired mechanotransduction of pericytes |
Altered mechanotransduction properties of pericytes |
Cellular |
| 1947 |
Pericyte dysfunction |
Pericyte dysfunction |
Cellular |
| 1948 |
Increased ACE2 expression |
Upregulation of ACE2 |
Molecular |
| 1949 |
Decrease, GLUT4 |
Decrease, GLUT4 |
Cellular |
| 1950 |
Increase, TNF |
Increase, TNF |
Molecular |
| 1951 |
Decrease, Glucose uptake |
Decrease, Glucose uptake |
Cellular |
| 1952 |
Abnormal, Glucose homeostasis |
Abnormal, Glucose homeostasis |
Organ |
| 1953 |
Gestational diabetes mellitus |
GDM |
Individual |
| 1954 |
Gut microbiota, alteration |
Gut dysbiosis |
Organ |
| 1955 |
Acute Myeloid Leukemia |
AML |
Individual |
| 1956 |
Binding to hERG channel |
Binding to hERG channel |
Molecular |
| 1957 |
hERG channel biogenesis interference |
hERG channel biogenesis interference |
Molecular |
| 1958 |
Direct hERG channel blockage |
Direct hERG channel blockage |
Cellular |
| 1959 |
Induction of hERG trafficking defects |
Induction of hERG trafficking defects |
Cellular |
| 1960 |
Inhibition of Ikr |
Inhibition of Ikr |
Tissue |
| 1961 |
Prolongation of Action Potential Duration |
Prolongation of Action Potential |
Organ |
| 1962 |
Prolongation of QT interval |
Prolongation of QT interval |
Organ |
| 1963 |
Torsades de Pointes |
Torsades de Pointes |
Organ |
| 1964 |
Sudden cardiac death |
Sudden cardiac death |
Individual |
| 1965 |
Increase, Pollen abnormal |
Increase, Pollen abnormal |
Organ |
| 1966 |
Decrease, Asexual reproduction |
Decrease, Asexual reproduction |
Individual |
| 1967 |
Pyroptosis |
Pyroptosis |
Cellular |
| 1968 |
Increase, Mitochondrial Dysfunction |
Increase, Mt Dysfunction |
Cellular |
| 1969 |
Increase, Oxidative Stress |
Increase, Oxidative Stress |
Molecular |
| 1970 |
transposition of the great arteries |
Transposition of the great arteries |
Organ |
| 1971 |
Increased, tumor growth |
tumor growth |
Organ |
| 1972 |
Increased, Steroidogenic acute regulatory protein (StAR) |
Increased, Steroidogenic acute regulatory protein (StAR) |
Cellular |
| 1973 |
Increased, estrogens |
Increased, estrogens |
Cellular |
| 1974 |
Activation of Tumor Protein 53 |
Activation of TP53 |
Cellular |
| 1977 |
Disruption of sodium channel gating kinetics |
Altered kinetics of sodium channel |
Cellular |
| 1978 |
Increase risk, microcephaly |
Microcephaly |
Individual |
| 1979 |
Premature cell differentiation |
Premature differentiation |
Organ |
| 1980 |
Increased micro RNA expression |
Increase,miRNA levels |
Cellular |
| 1981 |
Decreased SIRT1 expression |
Decrease,SIRT1(sirtuin 1) levels |
Cellular |
| 1982 |
metastatic breast cancer |
Metastasis, Breast Cancer |
Organ |
| 1983 |
Disruption, action potential |
Disruption in action potential generation |
Cellular |
| 1984 |
Agonism, Estrogen Receptor alpha |
Agonism, Estrogen Receptor alpha |
Molecular |
| 1985 |
Increased, Kisspeptin signalling |
Increased, Kisspeptin signalling |
Molecular |
| 1986 |
Decreased, Gonadotropins |
Decreased, Gonadotropins |
Molecular |
| 1987 |
Decreased, Androgen and Progestin |
Decreased , Androgen and Progestin |
Cellular |
| 1988 |
Decreased, Maturation Inducing Steroid Surge by Granulosa cells |
Decreased, Maturation Inducing Steroids Surge by Granulosa cells |
Tissue |
| 1989 |
Impaired, Oocyte maturation and ovulation |
Impaired, Oocyte maturation and ovulation |
Tissue |
| 1990 |
Increased, Oocyte Atresia |
Increased, Oocyte Atresia |
Tissue |
| 1991 |
Impaired, Reproduction |
Impaired, Reproduction |
Population |
| 1992 |
Increased incidence of respiratory morbidity and mortality in the general population |
Increased incidence of respiratory morbidity and mortality |
Population |
| 1993 |
Increase, Pneumonia |
Pneumonia |
Organ |
| 1994 |
Increase, Ferroptosis |
Ferroptosis |
Cellular |
| 1995 |
Abnormal lipid metabolism |
Abnormal lipid metabolism |
Cellular |
| 1996 |
Increased incidence of digestive morbidity and mortality in the general population |
Increased incidence of digestive morbidity and mortality |
Population |
| 1997 |
Colon epithelial injury |
Colon epithelial injury |
Organ |
| 1998 |
Activation, Microglia |
Microglia activation |
Cellular |
| 1999 |
Increased mortality of neurodegenerative diseases |
Increased mortality of neurodegenerative diseases |
Population |
| 2000 |
Vascular calcification |
Vascular calcification |
Organ |
| 2001 |
Cardiac hypertrophy |
Cardiac hypertrophy |
Organ |
| 2002 |
Ventricular remodeling |
Ventricular remodeling |
Organ |
| 2003 |
Vascular remodeling |
Vascular remodeling |
Organ |
| 2004 |
Increased, secretion of catecholamine |
Increased, secretion of catecholamine |
Cellular |
| 2005 |
Altered neurotransmission in development |
neurotrasmission in development |
Cellular |
| 2006 |
Secondary genotoxicity |
Secondary genotoxicity |
Cellular |
| 2007 |
Non-coding RNA expression profile alteration |
Non-coding RNA expression，alteration |
Molecular |
| 2008 |
Chronic obstructive pulmonary disease |
Chronic obstructive pulmonary disease |
Individual |
| 2009 |
Activation of inflammation pathway |
Activation, inflammation pathway |
Cellular |
| 2010 |
Pulmonary inflammation |
Pulmonary inflammation |
Organ |
| 2011 |
Emphysema |
Emphysema |
Organ |
| 2012 |
Fibroblast proliferation and differentiation |
Fibroblast proliferation and differentiation |
Cellular |
| 2013 |
Airway remodeling |
Airway remodeling |
Organ |
| 2014 |
Intestinal epithelial cell apoptosis |
Intestinal epithelial cell apoptosis |
Cellular |
| 2015 |
Intestinal inflammation |
Intestinal inflammation |
Organ |
| 2016 |
Hepatocyte cell apoptosis |
Hepatocyte cell apoptosis |
Cellular |
| 2017 |
Endoplasmic reticulum stress |
Endoplasmic reticulum stress |
Cellular |
| 2018 |
Insulin resistance |
Insulin resistance |
Cellular |
| 2019 |
Non-alcoholic fatty liver disease |
Non-alcoholic fatty liver disease |
Individual |
| 2020 |
Decrease, sox9 expression |
Decrease, sox9 expression |
Molecular |
| 2021 |
Increase, slincR expression |
Increase, slincR expression |
Molecular |
| 2022 |
Altered function of the brain |
brain function |
Organ |
| 2023 |
Inhibition of Ceramide Synthase |
Inhibition CerS |
Molecular |
| 2024 |
Reduced complex sphingolipids |
Reduced complex sphingolipids |
Cellular |
| 2025 |
Affected folate transporter |
Affected folate transporter |
Cellular |
| 2026 |
decreased folate uptake |
decrease folate |
Cellular |
| 2027 |
Antagonism, Smoothened receptor |
Antagonism Smoothened |
Molecular |
| 2028 |
Decrease, GLI1/2 translocation to nucleus |
Decrease, GLI1/2 translocation |
Molecular |
| 2029 |
protein-coupled estrogen receptor 1 (GPER) activation |
GPER activation |
Molecular |
| 2030 |
Activation, PARP1 |
PARP1 |
Molecular |
| 2031 |
Releasing, Apoptosis-Inducing Factor (AIF) |
AIF release |
Molecular |
| 2032 |
Viable offspring, decreased |
Viable offspring, decreased |
Individual |
| 2033 |
Increased sphingolipid-1-phosphate |
Increased S1-P |
Cellular |
| 2034 |
liver dysfunction |
liver dysfunction |
Organ |
| 2035 |
development, liver cancer |
development, liver cancer |
Tissue |
| 2036 |
Activation of metabotropic glutamate receptor |
Activation, mGLUr |
Molecular |
| 2037 |
Inositol triphosphate receptor activation |
Activation, IP3R |
Molecular |
| 2038 |
Activation of calpain signalling |
Activation, calpain |
Cellular |
| 2039 |
Inhibition GABAA receptor |
Inhibition, GABAAr |
Molecular |
| 2040 |
Decrease, GLI1/2 target gene expression |
Decrease, GLI1/2 target gene expression |
Cellular |
| 2041 |
Decrease, palatal shelf outgrowth |
Decrease, outgrowth |
Tissue |
| 2042 |
Orofacial clefting |
OFC |
Individual |
| 2043 |
Decrease, Sonic Hedgehog second messenger production |
Decrease, SHH second messenger production |
Cellular |
| 2044 |
Decrease, Smoothend relocation and activation |
Decrease, SMO relocation |
Cellular |
| 2045 |
Increase, Alcohol dehydrogenase |
Increase, Alcohol dehydrogenase |
Molecular |
| 2046 |
Increase, Vitellogenin mRNA |
Increase, Vitellogenin mRNA |
Molecular |
| 2047 |
Delay, Ovarian maturation |
Delay, Ovarian maturation |
Cellular |
| 2048 |
Increase, Body volume of female adults |
Increase, Body volume of female adults |
Individual |
| 2049 |
Increase, sex ratio (F/M) |
Increase, sex ratio (F/M) |
Individual |
| 2050 |
Increase, developmental abnormalities |
Increase, developmental abnormalities |
Individual |
| 2051 |
Decrease, Tyrosine |
Decrease, Tyrosine |
Molecular |
| 2052 |
Decrease, dopa decarboxylase |
Decrease, dopa decarboxylase |
Cellular |
| 2053 |
Increase, Defects in tanning of new cuticle |
Increase, Defects in tanning of new cuticle |
Individual |
| 2054 |
Increase, impairment of cuticle sclerotization |
Increase, impairment of cuticle sclerotization |
Individual |
| 2055 |
Increase, pigmentation |
Increase, pigmentation |
Individual |
| 2056 |
Increase, delay in oviposition |
Increase, delay in oviposition |
Individual |
| 2057 |
Decrease, hatching of egg |
Decrease, hatching of egg |
Individual |
| 2058 |
Decrease, 20-hydroxyecdysone |
Decrease, 20-hydroxyecdysone |
Molecular |
| 2059 |
Decrease, knickkopf gene |
Decrease, knickkopf gene |
Cellular |
| 2060 |
Decrease, Chitin laminar organization |
Decrease, Chitin laminar organization |
Tissue |
| 2061 |
Decrease, Prevent chitin degradation by chitinases |
Decrease, Prevent chitin degradation by chitinases |
Tissue |
| 2062 |
Weak, Procuticle protection |
Weak, Procuticle protection |
Organ |
| 2063 |
Decrease, New cuticle secretion |
Decrease, New cuticle secretion |
Organ |
| 2064 |
Increase, Cytosolic calcium |
Increase, Cytosolic Ca |
Cellular |
| 2065 |
Inhibition, Fatty acid oxidation |
Inhibition, Fatty acid oxidation |
Cellular |
| 2066 |
Altered Signaling Pathways |
Altered Signaling |
Molecular |
| 2067 |
Altered, Nitric Oxide Levels |
Altered, Nitric Oxide Levels |
Cellular |
| 2068 |
Increase, Endothelial Dysfunction |
Increase, Endothelial Dysfunction |
Tissue |
| 2069 |
Occurrence, Vascular Remodeling |
Occurrence, Vascular Remodeling |
Organ |
| 2070 |
Increase, Glycolysis |
Increase, Glycolysis |
Cellular |
| 2071 |
Decrease, Glucose pool |
Decrease, Glucose pool |
Cellular |
| 2072 |
Increase, Mitochondrial swelling |
Increase, Mitochondrial swelling |
Cellular |
| 2073 |
increase oxidation of the di-copper moiety of the hemocyanin active site |
methemocyanin formation (decrease overall oxygen binding capacity) |
Molecular |
| 2074 |
Decreased, oxygen binding capacity by hemocyanin |
Decrease overall oxygen binding capacity (methemocyanin formation) |
Molecular |
| 2075 |
Cognitive, sensed as hypoxic/low oxygen environment |
Hemocyanin Bohr effect decrease |
Organ |
| 2076 |
Increase, hemocyanin mRNA |
Increase, hemocyanin mRNA |
Tissue |
| 2077 |
Increase, pulmonate breathing |
behavioral change leading to possible reduced feeding opportunity |
Individual |
| 2078 |
Loss of drebrin |
Loss of drebrin |
Cellular |
| 2079 |
Increased, glycolipid levels |
Increased glycolipid levels |
Cellular |
| 2080 |
Impaired, blood testis barrier |
Impaired, blood testis barrier |
Organ |
| 2081 |
Increased Modified Proteins |
Modified Proteins |
Molecular |
| 2082 |
Hypospadias, increased |
Hypospadias |
Organ |
| 2083 |
Occurrence of Cataracts |
Cataracts |
Organ |
| 2084 |
Increase, Cardiac remodelling |
Increase, Cardiac remodelling |
Tissue |
| 2085 |
Alveolar epithelial injury |
Alveolar epithelial injury |
Cellular |
| 2086 |
Airway inflammation |
Airway inflammation |
Organ |
| 2087 |
Increased incidence of respiratory disease |
Increased incidence of respiratory disease |
Individual |
| 2088 |
Dysfunction of respiratory system |
Respiratory dysfunction |
Individual |
| 2089 |
Altered Bone Cell Homeostasis |
Altered Bone Cell Homeostasis |
Cellular |
| 2090 |
Increase, Bone Remodeling |
Bone Remodeling |
Tissue |
| 2091 |
Occurrence, Bone Loss |
Bone Loss |
Organ |
| 2092 |
Promotion, Ovarian Cancer |
Promotion, Ovarian Cancer |
Organ |
| 2093 |
Brain thyroid hormone (T4/T3) decreased |
Decreased brain T4/T3 |
Organ |
| 2094 |
Abnormal, neuroblast migration |
Abnormal cell migration in brain |
Cellular |
| 2095 |
Periventricular heterotopia formation |
Heterotopia formation |
Individual |
| 2096 |
Occurrence, (Micro)vascular dysfunction |
(Micro)vascular dysfunction |
Tissue |
| 2097 |
Increase, Pro-Inflammatory Mediators |
Increase, Pro-Inflammatory Mediators |
Tissue |
| 2098 |
Increase, Neural Remodeling |
Increase, Neural Remodeling |
Tissue |
| 2099 |
hERG channel blockade |
hERG channel blockade |
Molecular |
| 2100 |
Inhibition of rapid delayed rectifying potassium current |
Inhibition of rapid delayed rectifying potassium current |
Cellular |
| 2101 |
Conformational changes of thyroid receptor |
Conformational changes of thyroid receptor |
Molecular |
| 2102 |
Cytotoxicity (human trophoblast cells) |
Cytotoxicity (human trophoblast cells) |
Cellular |
| 2103 |
Cellular dysfunction (human placenta trophoblast cells) |
Cellular dysfunction (human placenta trophoblast cells) |
Cellular |
| 2104 |
Decreased, thyroid hormone binding to thyroid hormone receptor |
Decreased, TH binding to THR |
Molecular |
| 2105 |
Decreased, myelin basic protein expression in oligodendrocytes |
Decreased, mbp expression in oligodendrocytes |
Molecular |
| 2106 |
Impaired, oligodendrocyte maturation |
Impaired OL maturation |
Cellular |
| 2107 |
Hypomyelination |
Hypomyelination |
Tissue |
| 2108 |
Altered, white brain matter |
Altered, white brain matter |
Tissue |
| 2109 |
Binding, extracellular matrix protein laminin |
Binding to laminin |
Molecular |
| 2110 |
Disrupted binding, laminin-beta1-integrin receptors with laminin |
binding beta1integrin receptors with laminin |
Molecular |
| 2111 |
Decreased, neural progenitor cell adhesion to laminin |
NPC adhesion to laminin |
Cellular |
| 2112 |
Disturbed, radial glia cell alignment and migration |
RG alignment and migration |
Cellular |
| 2113 |
Decreased, radial glia cell density |
RG density |
Cellular |
| 2114 |
Disturbed, cortical architecture |
Disturbed cortical architecture |
Organ |
| 2115 |
Altered, cholesterol metabolism |
Cholesterol metabolism |
Molecular |
| 2116 |
Decreased, oligodendrocyte differentiation |
Oligodendrocyte differentiation |
Cellular |
| 2117 |
Increase, goblet cell number |
Increase, goblet cell number |
Cellular |
| 2118 |
Succinate dehydrogenase, inhibited |
SDH, inhibited |
Molecular |
| 2119 |
Insulin resistance, increased |
Insulin resistance, increased |
Individual |
| 2120 |
Superoxide generation, increased |
Superoxide generation, increased |
Cellular |
| 2121 |
decreased, Intellectual Quotient |
decreased, IQ |
Population |
| 2122 |
increased, Economic Burden |
increased, Economic Burden |
Population |
| 2123 |
decreased, Bcl-2 expression |
decreased, Bcl-2 expression |
Molecular |
| 2124 |
increased, Bax expression |
increased, Bax expression |
Molecular |
| 2125 |
Increased fat mass |
Increased fat mass |
Organ |
| 2126 |
Estrogen receptor alpha inactivation |
ERa inactivation |
Molecular |
| 2127 |
Increased adipocyte size |
Increased adipocyte size |
Cellular |
| 2128 |
Increased adipocyte numbers |
Increased adipocyte numbers |
Cellular |
| 2129 |
Metabolically unhealthy Obesity |
Metabolically unhealthy Obesity |
Individual |
| 2130 |
increased lipid accumulation |
increased lipid accumulation |
Cellular |
| 2131 |
Conjugation, Glutathione |
Conjugation, Glutathione |
Cellular |
| 2132 |
Increased pro-inflammatory cytokine expression |
Increased cytokine expression |
Cellular |
| 2133 |
Increase, Glucuronidation of T4 |
Increase, Glucuronidation of T4 |
Molecular |
| 2134 |
Increase, Androgen receptor |
Increase, Androgen receptor |
Molecular |
| 2135 |
Prostate cancer |
Prostate cancer |
Individual |
| 2136 |
prostatic intraepithelial neoplasia |
prostatic intraepithelial neoplasia |
Tissue |
| 2137 |
Increase, Gonadotropins concentration in plasma |
Increase, Gonadotropins concentration in plasma |
Tissue |
| 2138 |
Reduction,Testosterone concentration in plasma |
Reduction,Testosterone concentration in plasma |
Tissue |
| 2139 |
Reduction, the ratio of 17beta-estradiol/11-Keto Testosterone in plasma |
Reduction, the ratio of E2/11-KT in plasma |
Organ |
| 2140 |
Decreased spawning and cumulative fecundity, decreased gonadosomatic index |
Decreased spawning and cumulative fecundity, decreased GSI |
Individual |
| 2141 |
Disruption, Estrogen receptor |
Disruption of ER |
Molecular |
| 2142 |
Depletion, Ectoplasmic specialization (ES) |
Depletion of ES |
Cellular |
| 2143 |
Increased, gene expression of AR |
Increased, gene expression of AR |
Molecular |
| 2144 |
Impaired insulin signaling |
Impaired insulin signaling |
Cellular |
| 2145 |
Metabolic syndrome |
Metabolic syndrome |
Population |
| 2146 |
Activation of mitogen-activated protein kinase kinase, extracellular signal-regulated kinase 1/2 |
Activation of MEK, ERK1/2 |
Cellular |
| 2147 |
Decreased, Viable Offspring |
Decreased, Viable Offspring |
Individual |